



**CRF Completion Guidelines (CCGs)**  
**Protocol #: MTN-044/IPM 053/CCN019**  
**V3.0 (11 Jun 2019)**

---

## Table of Contents

Completion Guidelines for Standard CRFs .....	4
<b>ADMINISTRATIVE FORMS.....</b>	<b>12</b>
Participant Identifier .....	12
Screening Date of Visit .....	12
Inclusion/Exclusion Criteria .....	13
Randomization .....	13
Demographics .....	14
Enrollment.....	15
Follow-up Visit Y/N .....	15
Follow-up Visit Summary.....	16
Phone follow-up .....	17
Protocol Deviation Summary.....	18
Protocol Deviation Log .....	18
Additional Study Procedures .....	20
Interim Visit Summary.....	20
Missed Visit .....	22
Study Discontinuation .....	22
<b>RING FORMS .....</b>	<b>23</b>
Pharmacy Dispensation .....	23
Ring Insertion and Removal.....	24
<b>CLINICAL FORMS.....</b>	<b>25</b>
Physical Exam .....	25
Vital Signs .....	26
Pelvic Exam.....	26
Pelvic Exam Diagrams Form .....	27
Baseline Medical History Y/N .....	28
Baseline Medical History Log.....	28
Adverse Events Y/N .....	31
Adverse Event Log.....	31
Concomitant Medications Y/N .....	34
Concomitant Medications Log.....	35
Product Hold Summary .....	37

**CONFIDENTIAL DOCUMENT**

---

Product Hold Log.....	37
Product Discontinuation.....	39
Pregnancy Report.....	40
Pregnancy History.....	41
Pregnancy Outcome Log.....	41
Screening Menstrual History.....	43
Enrollment Menstrual History.....	44
Vaginal Bleeding Assessment.....	45
<b>LABORATORY FORMS.....</b>	<b>46</b>
HIV Test Results.....	46
HIV Confirmatory Tests.....	47
STI Test Results.....	48
Local Laboratory Results.....	49
Hematology.....	52
Hormone Tests.....	55
Pregnancy Test Results.....	55
Specimen Storage.....	56
<b>BEHAVIORAL FORMS.....</b>	<b>57</b>
Baseline Behavioral Questionnaire.....	57
PUEV Behavioral Questionnaire.....	58
Ring Outage SMS.....	59
Bleeding SMS.....	62

## Completion Guidelines for Standard CRFs

The following instructions are study-specific data completion instructions intended to assist site staff when completing Case Report Forms (CRFs) for MTN-044/IPM 053/CCN019 (Detailed guidance on general data collection, entry, navigation and general use of Medidata Rave is provided in the Medidata Rave Electronic Data Capture (EDC) Training Manual, which is posted on the MTN-044 Atlas web page: <https://atlas.scharp.org/cpas/project/MTN/044/begin.view?>)

### General Guidelines – Medidata Rave eCRFs (electronic CRF completion)

- The Participant ID is automatically assigned by Rave as a 9-digit field, starting with the 3-digit site number followed by a randomly assigned 6-digit participant number.
- All data entered in the eCRF should correspond accurately with the source documents/paper CRFs.
- Complete all required fields on the screens. Please ensure all entries are in English and are accurate, consistent, complete and medically logical.
- Ensure there are no missing data in the eCRF. Where requested to ‘specify’ for an item, ensure that a specific entry is made.
  - Visit dates should be complete and chronological according to the protocol.
  - All date fields are entered as Day/Month/Year (dd/mmm/yyyy) (e.g., 16 APR 2017).
- Drop-down menus are available for many fields. Use these menus, when available, to select the appropriate response.
- Avoid using abbreviations and symbols wherever possible. Do not use special characters unless explicitly stated or hit the Return key in text fields.
- If a scheduled visit was missed, do not enter data on any of the eCRF pages for the visit, with the exception of the Follow-up Visit Y/N, and the Missed Visit eCRFs, which should be completed.
- Log (or repeating) forms have been provided. Log forms allow you to enter multiple items on one form, and to switch between portrait and log formats for ease of viewing or data entry. The following are log forms for this study: Adverse Events Log, Concomitant Medications Log, Protocol Deviations Log, Pregnancy Outcome Log, Baseline Medical History Log, and Product Hold Log. Some forms have log fields. The following are forms with log fields: Specimen Storage, Inclusion/Exclusion Criteria, Bleeding SMS, and Ring Outage SMS, and Pharmacy Dispensation.
  - Click “Add a new Log line” to add a row.
  - Log lines can be inactivated by clicking “Inactivate” and specifying the log line number if needed.
- If corrections are needed: By clicking the “pencil” icon, the field will become editable so that you can then correct the value and give the reason for the change (if needed).
- In case of an incorrect data entry, a system query will fire. System queries will close automatically after saving the form if the data point is entered or corrected (A response to the system query is not required). However, answering a system query prior to updating the data point field will make the query change into a manual query that will need to be closed by SCHARP.
- Data changes can be reviewed in the audit trail. If data is modified inadvertently, the change is also saved in the audit trail.

CONFIDENTIAL DOCUMENT

- The Investigator of Record (IoR) will sign all pages after the participant's data has been reviewed, no further changes or additions to the eCRFs are necessary and the casebook status is frozen. The SCHARP Clinical Data Manager(s) will provide directions for the timing of when the Investigator should perform the final review and sign the eCRF pages.

### Add Event

- The **Add Event** drop-down menu can add select forms and visits to a participant's casebook.
- The following folders can be added to a participant's casebook:
  - Interim Visits (see section on "Interim Visits" on how to add interim visits to a participant's casebook)
  - Pregnancy
- The following form can be added to the Enrollment folder in a participant's casebook:
  - STI Test Results

### Interim Visits

- Should unscheduled assessments be required for a non-routine visit or procedure, add the visit by clicking on the **Add Event** button. Select "Interim Visit". An Interim Visit folder will appear in the participant's casebook.
- Open the Interim Visit folder to access the "Interim Visit Summary" eCRF. On the Interim Visit Summary eCRF, select "Yes" for each assessment that was performed. The selected forms will be populated automatically within the applicable Interim Visit folder.
- On the Interim Visit Summary eCRF, enter the visit date as the earliest date visit procedures performed at the visit began.

### Auto-population of Medidata Rave Forms

- Medidata Rave will dynamically add folders and eCRFs to a visit folder within a participant's casebook based on specified responses on the eCRFs. Below are a few examples:
  - Example 1: Randomization eCRF - Enrollment folder
    - If "Yes" is selected for "Is the participant ready to be randomized", folders will be added for visits 3.0 – 15.0, Discontinuations and Pharmacy (for Pharmacists only to complete).
  - Example 2: Follow up Visit Y/N eCRF
    - If item "Did the participant complete this visit?" is marked 'no', the Missed Visit eCRF will be added to the visit folder.
    - If item "Did the participant complete this visit?" is marked 'Yes', the Follow-up Visit Summary eCRF will be added to the visit folder.
  - Example 3: Adverse Event Y/N eCRF
    - Selecting 'Yes' for "Has the participant experienced an Adverse Event during the study?" will dynamically add the Adverse Event Log eCRF to the Ongoing Logs folder.

### Dynamic Search List Functionality

- Dynamic searchlist functionality is used to look up Adverse Events data (*AE log line, start date, and term, e.g. "#001 05JAN2017-FEVER"*).
- Dynamic searchlist functionality is present on the following eCRFs: Concomitant Medications, Hematology, Local Laboratory Results, Pelvic Exam, Pregnancy Outcome Log, Product Discontinuation, Product Hold Log, Study Discontinuation, and Vaginal Bleeding Assessment.
- For Example:
  - An AE of 'FEVER' started on 05JAN2017 and is reported on the Adverse Events eCRF
  - On the Concomitant Medications form, if a listed medication was taken for this AE, a dynamic searchlist should be used to select the applicable AE record from the dropdown list.
  - The dynamic search list for 'AE log line, start date, and term' shows records entered on the AE form
  - Your selection can be manually deleted if entered in error
    - **Note:** If the original data (e.g., AE term and/or start date, MH term) changed or the log line was inactivated, the previous selection becomes non conformant. You will need to correct the item by re-selecting from the search list to correspond with the latest data.


### Source Document fields

- Many eCRFs include a 'Source Document' field that can be used to upload source documents. One source document file can be uploaded per form. Multiple source document files can be saved in a compressed (zipped) folder, and the compressed folder can be uploaded.
- The Source Document field on the Adverse Event Log form should be used to upload source documents if an SAE is reported.
- On all other forms, the source document field should be used to upload source documents when required for Source Document Verification. Do not upload any documents for SDV unless instructed to do so by the Clinical Data Manager or Clinical Research Associate/Monitor.
- All identifiable information must be redacted prior to uploading documents to Rave.

### Icon Key

Within Rave, an Icon Key is available. The key contains a description and picture of the commonly used icons. To access the Icon Key, click on the Icon Key hyperlink. The Icon Key will open in a separate pop-up window. Below is a screen shot of the Icon Key.


**Figure 1. Icon Key**



**Icon Progressions**

The life cycle of folders, forms, fields, etc., follows a logical progression starting with never touched and moving toward complete and locked. Graphical icons are used throughout Rave to visually denote status.

The following figure illustrates the status represented by each icon, and the progression of icons through the life cycle.



**Task Summary**

- The Task Summary Listing displays all pending tasks for a study. At the Site level, it displays the number of participants within the site that contain the selected item (see Figure 3). For example, 8 participants within the site have open queries. If the “Open Queries task is expanded, the 8 participants are displayed (see Figure 4).

Figure 3. Site-Level Task Summary

Task Summary: Site	Subjects
▶ Requiring Signature	8
▶ NonConformant Data	0
▶ Open Queries	8
▶ Overdue Data	0

Figure 4. Site-Level Task Summary

Task Summary: Site	Subjects
▶ Requiring Signature	8
▶ NonConformant Data	0
▼ Open Queries	8
998210855	
998238757	
998313907	
998329818	
998423107	
998549894	
998561588	
998672732	
1	
▶ Overdue Data	0

- At the Subject (participant) level, the Task Summary displays the number of pages/forms for the participant that contain the selected item. In Figure 5 below, there are 3 open queries on 3 eCRFs. In the expanded task summary view, if a form name is clicked that form is displayed.

Figure 5. Subject-Level Task Summary

Task Summary: Subject	Pages
▶ Requiring Signature	1
▶ NonConformant Data	0
▼ Open Queries	3
V1.0 - Screening-Hematology	
<a href="#">V1.0 - Screening-Baseline Medical History Summary</a>	
V1.0 - Screening-Baseline Medical History Log	
1	
▶ Overdue Data	0

**General Guidelines – Paper CRF Completion**

When completing a paper CRF, refer to detailed instructions on data collection pertaining to the specific form and fields on that form in this document.

Based on Good Clinical Practices (GCPs), the following guidelines should be used for completing paper CRFs:

- Use a black or dark blue medium ballpoint pen. Do not use any other type of writing tool.
- Press firmly when recording data or writing comments.
- Print all data and comments legibly by hand. Entries that cannot be read may result in incorrect data entry.
- Do not use cursive/script handwriting, as it can be difficult to read.
- Write numbers as large as possible on the line specified.
- Record data on the front of CRFs only.

- If the lines provided for written responses are not long enough, continue in another blank area of the form (within the page margins).
- Mark only one answer except when given the instruction “Mark/Select all that apply.”
- A response is required for every item unless instructed otherwise by a skip pattern, as noted in the CCGs.
- **Never** use correction fluid (“white-out”) or correction tape on CRFs.

### How to Record Dates - Electronic and/or Paper

Dates are entered using the “dd MMM yyyy” format, where “dd” represents the two-digit day, “MMM” represents the three-letter abbreviation of the month, and “yyyy” represents the four digits of the year.

The month field must be entered with the three-letter abbreviation in English. Abbreviations are shown below. In the study database, these abbreviations will be selected from a drop-down list in the month field.

Month	Abbreviation	Month	Abbreviation
January	JAN	July	JUL
February	FEB	August	AUG
March	MAR	September	SEP
April	APR	October	OCT
May	MAY	November	NOV
June	JUN	December	DEC
Unknown	UNK		

For example, September 20, 2016 is recorded as:

The screenshot shows a date entry interface with three input fields: a day field containing '20', a month dropdown menu currently showing 'Sep' with a downward arrow, and a year field containing '2016'. The dropdown menu is open, displaying a list of month abbreviations: '...', 'Jan', 'Feb', 'Mar' (highlighted in blue), 'Apr', 'May', 'Jun', 'Jul', and 'Aug'. To the right of the dropdown is a 'Sav' button.

Some items allow for partial dates. When recording partial dates, the following guidance applies:

- Enter UN for the day
- Select “UNK” for the month from the drop-down menu.

### How to Record Time - Electronic and/or Paper

Time is recorded on CRFs using the 24-hour clock (00:00-23:59), in which hours are designated from 0–23. For example, in the 24-hour clock 2:25 p.m. translates to 14:25 (2 p.m. = 14), which would be recorded as follows:

CONFIDENTIAL DOCUMENT

14 25 24-hour clock

Midnight is recorded as 00:00, not 24:00.

The following chart shows equivalencies between the 12- and 24-hour clocks:

12-hour clock (a.m.)	24-hour clock	12-hour clock (p.m.)	24-hour clock
Midnight	00:00	Noon	12:00
1:00 a.m.	01:00	1:00 p.m.	13:00
2:00 a.m.	02:00	2:00 p.m.	14:00
3:00 a.m.	03:00	3:00 p.m.	15:00
4:00 a.m.	04:00	4:00 p.m.	16:00
5:00 a.m.	05:00	5:00 p.m.	17:00
6:00 a.m.	06:00	6:00 p.m.	18:00
7:00 a.m.	07:00	7:00 p.m.	19:00
8:00 a.m.	08:00	8:00 p.m.	20:00
9:00 a.m.	09:00	9:00 p.m.	21:00
10:00 a.m.	10:00	10:00 p.m.	22:00
11:00 a.m.	11:00	11:00 p.m.	23:00

### **Documentation of Numbered responses (non-dates)**

When recording numbered responses, please enter the whole number without leading zeros. Instead of '00', this should be recorded as '0'. 3 should be recorded as 3, not '03' and so on. For example, if the participant's rate of respiration is 9 breaths per minute, the response to this question on Vital Signs eCRF should be recorded as "9".

### **Data Corrections and Additions - Electronic and/or Paper**

Sometimes, data on a CRF (paper or electronic) may need to be changed, clarified, or amended. There are many reasons why data may need to be changed, such as in response to a query or as a result of site review.

If the electronic CRF is source, it is sufficient to make data updates in the study database itself. If a paper CRF is completed, it is important to make changes to the original CRF first, then enter the updated data into the study database.

***Note for paper CRFs:*** Never write over an entry once it is recorded. Use the standards outlined in the following paragraphs when changing, clarifying, or amending data.

Whenever an entry on a paper CRF is changed, do the following:

- draw a single horizontal line through the incorrect entry (do not obscure the entry or make it un-readable with multiple cross-outs),
- place the correct or clarified answer near the box, and

If an X is marked in the wrong response box, correct it by doing the following:

- draw a single horizontal line through the incorrectly marked box,

- mark the correct box, and
- initial and date the correction as shown below:

Yes  *mp 01-Aug-16*  
 No

If the correct answer has previously been crossed out, do the following:

- circle the correct item,
- write an explanation in the white space near the item, and
- initial and date all corrections as shown below:

Yes  *mp 18-AUG-16*  
 No  *"should be YES" jb-20-AUG-16*

The standards above must *always* be followed whenever a paper CRF is changed, clarified, or amended.

### How to Handle Missing and Unknown Data

If the answer to an item is not known, is not available, or if the participant refuses to answer for a required item:

- On paper CRFs: draw a single horizontal line through the applicable item and initial and date the item for which the data is unknown. It is helpful to write “don’t know,” “refuses to answer,” “UNK” (unknown), “N/A” (not applicable), or “REF” (refused) near the fields.

For example, when recording a date, if the exact day is not known, write “un” to designate the “dd” (or date) and write “don’t know” next to the response, as shown below. Initials and date are required for any data item that is refused, missing, unknown, or not applicable, regardless of whether it is marked as such during the initial paper form completion, or as an update to the form.

*mp*  
~~18-AUG-16~~ *don't know exact date*  
 un FEB 14

---

- On eCRFs: enter “UN” or select the “UNK” option from the drop-down list of the applicable field for which the data is missing/unknown.

A skip pattern, as noted in the CCGs, is the **only** valid reason to leave a response blank.

## ADMINISTRATIVE FORMS

### *Participant Identifier*

**Purpose:**

The Participant Identifier page within Medidata Rave will generate each participant’s PTID. This page is the first form completed within Medidata Rave for each participant.

**General Instructions:**

Complete this form for every MTN-044 participant once she has provided written informed consent for study screening and enrollment.

**Item-specific Instructions:**

Field	Instructions				
Participant ID	<p>To add a participant to the study database, select the “Add Subject” link on the MTN-044 site-specific home page. The Participant Identifier page will appear. This is the first page that should be completed for each participant.</p> <p>No data entry is required by the site on this form. Click the “Save” button at the bottom of the form. A pop-up box will appear to indicate that a participant has been added to the database and the home page for the participant’s file will appear. The link to refer back to the Participant Identifier page is located at the top of each participant’s home page. The participant ID will appear on each eCRF generated in Medidata Rave. The participant ID should be written at the top of each paper CRF completed for a participant.</p> <p>The first three digits of each participant ID will comprise of the Rave site ID. Therefore, each participant ID will begin with the site ID. A list of Rave site IDs is provided in the table below:</p> <table border="1" data-bbox="396 1549 1159 1619"> <thead> <tr> <th data-bbox="396 1549 911 1581">CRS Name</th> <th data-bbox="911 1549 1159 1581">Rave Site ID</th> </tr> </thead> <tbody> <tr> <td data-bbox="396 1581 911 1619">Pittsburgh</td> <td data-bbox="911 1581 1159 1619">702</td> </tr> </tbody> </table>	CRS Name	Rave Site ID	Pittsburgh	702
CRS Name	Rave Site ID				
Pittsburgh	702				

### *Screening Date of Visit*

**Purpose:**

This form is used to document the date of the participant’s Screening Visit.

CONFIDENTIAL DOCUMENT

**General Instructions:**

If screening procedures are conducted across multiple days, this date should correspond to the first day on which screening procedures are done. If a participant has a second screening attempt, update this form with the date from the second screening attempt. Do not complete a new form.

***Inclusion/Exclusion Criteria*****Purpose:**

This form is used to document date of informed consent, participant eligibility for enrollment in MTN-044, and if applicable, type of ineligibility and reasons for study ineligibility per the inclusion and exclusion criteria per protocol.

**General Instructions:**

Complete this form for each participant screened in MTN-044 when it is determined whether the participant will enroll in the study. If a participant has a second screening attempt, update this form with data from the second screening attempt. Do not complete a new form.

**Item-specific Instructions:**

Field	Instructions
Did the participant meet all eligibility criteria?	Select 'Yes' or 'No'.
Informed Consent Date	Date of screening informed consent.  If a participant undergoes a second screening attempt, update with the new informed consent date.
Eligibility Status	Select 'Eligible and Enrolled', 'Eligible/Not enrolled', 'Ineligible', or 'Incomplete Screening' from the drop-down list.  If 'Eligible and Enrolled', or "Incomplete Screening", end the form.
Select reason(s) why participant is ineligible	Complete this item only if the response to 'Did the participant meet all eligibility criteria?' is 'No'. Select all Inclusion or Exclusion criteria that were not met from the drop-down list. Add a new log line for each criterion, as needed.
Additional details about why subject did not qualify	For all ineligible participants, complete this item to provide additional details about why a participant was ineligible to participate.

***Randomization*****Purpose:**

This form is used to officially randomize eligible participants to a ring use group for MTN-044.

**General Instructions:**

The Randomization CRF is completed for each enrolled MTN-044 participant.

**CONFIDENTIAL DOCUMENT**

Complete this form for each participant who will enroll in MTN-044 at the Enrollment Visit. The Randomization Date and Time will be auto-populated from Medidata Balance into Medidata Rave. (NOTE: The time zone is GMT, not the time zone where data is being entered.) Completion of this eCRF will generate the participant's treatment assignment in Medidata Balance. "Eligibility status" on the Inclusion/Exclusion Criteria eCRF must be "Eligible and enrolled" in order for the randomization to be successful.

**Item-specific Instructions:**

Field	Instructions
Is the participant ready to be randomized?	<p>If the participant is eligible to be enrolled, select 'Yes' and Save the form. If the participant is successfully randomized, a note will appear under this item as shown below:</p> <div style="border: 1px solid gray; padding: 5px; margin: 10px 0;"> <p><b>Is the participant ready to be randomized?</b>  <input type="checkbox"/> Subject successfully randomized.</p> </div> <p>If randomization was not successful, this message will not appear and the Randomization Date and Time will not automatically populate.</p> <p>If successful, the participant will be assigned to a ring use group in the Medidata Balance module.</p>
Randomization Date and Time	<p>Once "Is the participant ready to be randomized?" is saved as 'Yes', then the randomization Date and Time will automatically populate.</p> <p>The Randomization Time will be auto-populated in Coordinated Universal Time (UTC).</p>

## *Demographics*

**Purpose:**

This form is used to document a participant's demographic and socioeconomic information.

**General Instructions:**

This form is completed at the Screening Visit. Responses should reflect the participant's status at screening, and should not be changed after screening unless correction is needed.

**Item-specific Instructions:**

Field	Instructions
Date of birth?	Please provide the participant's date of birth. A complete date is required.
Age	This is an automatically derived, locked data field based on the participant's date of birth and the date of initial data entry. No data entry is required.
Sex at Birth	Select the applicable response from the drop-down list.

CONFIDENTIAL DOCUMENT

Field	Instructions
Ethnicity	This item is based on self-definition. Per NIH policy, Latina or Hispanic includes a person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race.
Race	Record the participant's race based on self-definition. In the case of mixed race, mark all that apply. If a race is other than those listed, select 'Other race' and specify in the 'Other race, specify' text field provided. Per NIH policy, Latina is considered an ethnic group and not a race, and should not be entered as a Race.
Highest education level completed	Select the applicable response from the drop-down list based on the participant's response.
Relationship status	Complete this item based on participant self-report.
Do you currently have a primary sex partner?	Select 'Yes' or 'No'.  If 'No', then end of form and leave remaining items referring to primary sex partner blank.
Is your primary sex partner a man or a woman?	If 'Other' is selected, then record the participant's response in the "If other, specify" text field provided.

## ***Enrollment***

### **Purpose:**

This form is used to document a participant's consent to long-term specimen storage and a participant's group assignment. This form is completed at Enrollment for participants who have provided informed consent and who are eligible to participate in the study.

### **General Instructions:**

Complete this form for each participant who is enrolled into MTN-044. This form is present at the V2.0 – Enrollment visit.

### **Item-specific Instructions:**

Field	Instructions
Did the participant consent to long-term specimen storage and future testing?	Select 'Yes' or 'No'.  Consent for long-term specimen storage can be changed if the participant changes her consent decision after enrollment. Update as needed if the participant changes her consent during the study.
Group assignment	The participant's group assignment will be automatically populated by Medidata Balance when a participant is successfully randomized.

## ***Follow-up Visit Y/N***

### **Purpose:**

This form documents if a scheduled follow-up visit was conducted.

**CONFIDENTIAL DOCUMENT**

**General Instructions:**

This form is completed for each scheduled visit and is present in follow-up visit folders, starting at V3.0 – Day 2 through V14.0 – Day 93/94. Selecting ‘Yes’ will add the ‘Follow-up Visit Summary’ eCRF to the visit folder. Selecting ‘No’ will add the ‘Missed Visit’ eCRF to the visit folder.

**Item-specific Instructions:**

Field	Instructions
Did the participant complete this visit?	Select ‘Yes’ or ‘No’.  If ‘Yes’ is selected, the ‘Follow-up Visit Summary’ form will be added to the visit folder and can then be completed. If ‘No’ is selected, the ‘Missed Visit’ form will be added to the visit folder and can then be completed.

***Follow-up Visit Summary*****Purpose:**

This form is used to summarize information from each participant follow-up study visit.

**General Instructions:**

This form is completed for each scheduled visit and is present in follow-up visit folders, starting at V3.0 – Day 1 through V14.0 – Day 93/94.

**Item Specific Instructions:**

Field	Instructions
Visit Date	A complete date is required.
Was study product permanently discontinued (scheduled or early) at this visit?	Select ‘Yes’ or ‘No’.  If ‘Yes’, then complete a Product Discontinuation eCRF within the Discontinuations folder.
Did the participant exit/terminate the study at this visit?	Select ‘Yes’ or ‘No’.  If ‘Yes’, then complete a Study Discontinuation eCRF within the Discontinuations folder.
Were any new adverse events (AEs) reported at this visit?	Select ‘Yes’ or ‘No’.  Select ‘Yes’ if at least one Adverse Event (AE) was newly completed for this visit. Navigate to the Ongoing Logs folder to complete an entry for the applicable AE(s).
Is the participant taking any concomitant medications that have not been previously reported?	Select ‘Yes’ or ‘No’.  Select ‘Yes’ if at least one concomitant medication was newly completed for this visit. Navigate to the Ongoing Logs folder to complete an entry for the applicable CM(s).

Were any protocol deviations been reported at this visit?	Select 'Yes' or 'No'.  Select 'Yes' if at least one protocol deviation was newly completed for this visit. Navigate to the Ongoing Logs folder to complete an entry for the applicable PD(s).
Were any additional study procedures or forms completed outside of the scheduled study visit per protocol?	Select 'Yes' or 'No'.  Select 'Yes' if additional procedures were completed at this visit to add the Additional Study Procedures CRF to the visit folder. Navigate to the Additional Study Procedures from to select the applicable study procedures.

### *Phone follow-up*

#### **Purpose:**

This form documents if a scheduled phone follow-up visit was conducted and summarizes information from each participant phone follow-up study visit.

#### **Generation Instructions:**

This form is completed for each scheduled phone visit and is present in follow-up visit folders V15.0 – Week 1 ARR, V16.0 – Week 4 ARR, V17.0 – Week 8 ARR, and V18.0 – Week 12 ARR.

Field	Instructions
Phone call date	A complete date is required.
Was an at-home pregnancy test done?	Select 'Yes' or 'No'.  If 'Yes', then complete 'At-home pregnancy test result'.
At-home pregnancy test result	Enter participant-reported result of at-home pregnancy test.
Is the participant taking a hormonal contraceptive?	Select 'Yes' or 'No'.
Has the participant's menses returned?	Select 'Yes' or 'No'.
Will the participant return for another Phone Follow-up visit?	Select 'Yes' or 'No'.
Were any new adverse events (AEs) reported at this visit?	Complete at visit 15 only. Select 'Yes' or 'No'.  Select 'Yes' if at least one Adverse Event (AE) was newly completed for this visit. Navigate to the Ongoing Logs folder to complete an entry for the applicable AE(s).
Is the participant taking any concomitant medications that have not been previously reported?	Complete at visit 15 only. Select 'Yes' or 'No'.  Select 'Yes' if at least one concomitant medication was newly completed for this visit. Navigate to the Ongoing Logs folder to complete an entry for the applicable CM(s).

**CONFIDENTIAL DOCUMENT**

Was the participant referred for evaluation of secondary amenorrhea?	Complete at visit 18 only. Select 'Yes' or 'No'.
--	--


### ***Protocol Deviation Summary***

**Purpose:**

This form documents if a protocol deviation has occurred.

**Generation Instructions:**

This form is present within the "Ongoing Logs" folder. Selecting 'Yes' in the "Protocol Deviations Summary" will add the "Protocol Deviation Log" eCRF.



**Item-specific Instructions:**

Field	Instructions
Have any protocol deviations occurred?	Select 'Yes' or 'No'.  If 'Yes' is selected, then the "Protocol Deviation Log" form appears dynamically within the Ongoing Logs folder and can then be completed.

### ***Protocol Deviation Log***

**Purpose:**

This form documents and reports protocol deviations identified for study participants during the implementation of MTN-044.

**General Information/Instructions:**

Complete this form each time a protocol deviation is identified. Once the Protocol Deviation Log form has been created, complete one page per protocol deviation when entering in the study database. To add an additional deviation within Medidata Rave, clicking "Add a new Log line" will add an additional page for a new deviation to be completed. Consult the MTN Regulatory Team (mtnregulatory@mtnstopshiv.org) and the Study Management Team if you are unsure if an event requires reporting as a deviation.

**Item-specific Instructions:**

CONFIDENTIAL DOCUMENT

Field	Instructions
Site awareness date	Record the date the site became aware of the deviation. A complete date is required.
Deviation date	Record the date the deviation occurred (start date). A complete date is required.
Type of deviation	Record the applicable deviation by selecting from the drop down menu.  <i>Please see table below for the types of deviations. When entering the type of deviation, the first few letters of the description can be entered within the drop-down search list to find the applicable deviation to be entered.</i>  Record "other" if none of the listed categories match.
Description of deviation	Use the text field to briefly describe the specific details of the deviation.
Plans and/or actions to address the deviation	Use the text field to provide a brief description of the plans to address the deviation.
Plans and/or actions to prevent future occurrences of the deviation	Use the text field to provide a brief description of the plans to address future deviations.
Deviation reported by	Enter the staff code of the site staff person who completed the form. Sites will need to assign a <b>four-digit</b> staff code to each site staff person who will be completing this form. This list is created, maintained and kept at the study site.

PROTOCOL DEVIATION CODE LIST	
Description	Description
<b>Inappropriate enrollment:</b> The participant enrolled and not all eligibility requirements were met.	<b>Unreported AE:</b> Site staff become aware of an AE, but do not report it per protocol requirements.
<b>Study product management deviation:</b> The site staff did not instruct the participant to hold, permanently discontinue, or resume study product use per protocol requirements.	<b>Unreported AE:</b> Site staff become aware of an SAE, but do not report it per protocol requirements.
<b>Study Product dispensing error:</b> The wrong study product was dispensed to a participant, or study product was dispensed to a participant who permanently discontinued study product use. Pharmacy staff must follow up with the MTN Pharmacist separately.	<b>Breach of confidentiality:</b> Include potential and actual cases where participant confidentiality is breached. For example, a staff member put a participant's name on a case report form.
<b>Study product sharing:</b> Participant has shared study product with another person or study participant.	<b>Physical assessment deviation:</b> Include missed or incomplete physical/pelvic exam assessments.
<b>Study product not returned:</b> Study product was not returned by the participant per protocol requirements.	<b>Lab assessment deviation:</b> Include missed, or incomplete lab specimen collection
<b>Conduct of non-protocol procedure:</b> A clinical or administrative procedure was performed that was not specified in the protocol, and was not covered under local standard of care practice.	<b>Mishandled lab specimen:</b> Include errors in labeling, physical handling, processing, testing, storage, or shipment of collected lab specimens.
<b>Improper AE follow-up:</b> use when an AE or SAE is not followed per protocol. For example, a clinical finding/lab result is not re-assessed as outlined in the protocol.	<b>Staff performing duties that they are not qualified to perform:</b> use for any instance when any study procedure, including clinical and administrative procedures, is completed by a staff member who is not adequately qualified AND delegated to perform the procedure.

CONFIDENTIAL DOCUMENT

<b>Use of non-IRB/EC-approved materials:</b> Include use of ANY study-related material that requires IRB or EC approval for use per site requirements.	<b>Questionnaire administration deviation:</b> A required questionnaire was not completed according to protocol requirements. Include instances where the wrong questionnaire was completed.
<b>Informed consent process deviation:</b> Examples include failure to accurately execute and/or document any part of the informed consent process.	<b>Counseling deviation:</b> Protocol-required counseling was not done and/or not documented correctly.
<b>Visit completed outside of window:</b> Use when visit procedures for a visit are done within the wrong window or not in a designated visit window. For example, if visit 3.0 procedures are done in the visit 4.0 window.	<b>Use of excluded concomitant medications, devices, or non-study products.</b>
<b>Other</b>	

### *Additional Study Procedures*

#### **Purpose:**

This form is used to record all additional procedures the participant received at his/her scheduled study visit (e.g., clinically indicated physical exam). Do not record any procedures required and performed per protocol on this form. Such procedures should be entered on the relevant CRF within the scheduled visit folder.

#### **General Instructions:**

The form is added dynamically to a visit folder when “Were any additional study procedures or forms completed outside of the schedule study visit per protocol?” is selected ‘Yes’ on the Follow-up Visit Summary CRF.

#### **Item-specific Instructions:**

<b>Field</b>	<b>Instructions</b>
Baseline Behavioral Questionnaire	Select this field to add the Baseline Behavioral Questionnaire form
Hematology	Select this field to add the Hematology form
HIV test	Select this field to add the HIV Test Results form
Hormone tests	Select this field to add the Hormone Tests form
Local labs	Select this field to add the Local Laboratory Results form
Pelvic exam	Select this field to add the Pelvic Exam form
Physical exam	Select this field to add the Physical Exam form
Pregnancy test	Select this field to add the Pregnancy Test Results form
PUEV Behavioral Questionnaire	Select this field to add the PUEV Behavioral Questionnaire form
Ring Insertion or Removal	Select this field to add the Ring Insertion and Removal form
Ring outage SMS	Select this field to add the Ring Outage SMS form
STI tests	Select this field to add the STI Test Results form
Vital signs	Select this field to add the Vital Signs form

### *Interim Visit Summary*

#### **Purpose:**

This form is used to summarize information from each participant at an interim visit and to record all procedures or assessments the participant received at any interim study visit (e.g., clinically indicated physical exam) that is completed during the study.

#### **General Information/Instructions:**

CONFIDENTIAL DOCUMENT

This form is required for each interim visit completed for a participant.

**Item-specific Instructions:**

Field	Instructions
Visit Date	A complete date is required.
Interim Visit code	Enter the applicable interim visit code. Refer to the Data Collection SSP for more information on visit codes.
Was study product held at this visit? If yes, complete a Product Hold form.	Select 'Yes' or 'No'.  If 'No', then complete a Product Hold eCRF within the Ongoing Logs folder.
Was study product use permanently discontinued (scheduled or early) at this visit? If yes, complete a Product Discontinuation form.	Select 'Yes' or 'No'.  If 'Yes', then complete a Product Discontinuation eCRF within the Discontinuations folder.
Did the participant exit/terminate the study at this visit?	Select 'Yes' or 'No'.  If 'Yes', then complete a Study Discontinuation eCRF within the Discontinuations folder.
Were any new adverse events (AEs) reported at this visit? If yes, complete the AE Log.	Select 'Yes' or 'No'.  Select 'Yes' if at least one Adverse Event (AE) was newly completed for this visit. Navigate to the Ongoing Logs folder to complete an entry for the applicable AE(s).
Is the participant taking any concomitant medications that have not been previously reported? If yes, complete the Concomitant Medications Log.	Select 'Yes' or 'No'.  Select 'Yes' if at least one concomitant medication was newly completed for this visit. Navigate to the Ongoing Logs folder to complete an entry for the applicable CM(s).
Have any protocol deviations been reported at this visit? If yes, complete the Protocol Deviations Log.	Select 'Yes' or 'No'.  Select 'Yes' if at least one protocol deviation was newly completed for this visit. Navigate to the Ongoing Logs folder to complete an entry for the applicable PD(s).
Reason for interim visit (Select all that apply.)	Select all that apply.  Mark the checkbox for each reason for the interim visit. Leave the checkbox unmarked for reasons that were not applicable.
<i>If yes, for which visit are procedures being made up?</i>	If "Completion of missed visit procedures" is 'Yes', then enter the applicable visit for which procedures are being made up.
<i>If other, specify</i>	If "Other" is selected for reason for interim visit, then specify the reason in the text field provided.

What study procedures were completed at this visit:	<p>Select all that apply. Mark the checkbox for the applicable procedures that were completed at the study visit. The applicable eCRF(s) will then be added to the participant's visit folder. For example, if a physical exam was performed, mark the checkbox for <b>Physical Exam</b>.</p> <p>Leave the checkbox unmarked for procedures that were not completed at the study visit.</p>
---	---

### *Missed Visit*

#### **Purpose:**

Complete this form whenever an enrolled participant missed a required visit according to the visit window outlined in the protocol or Study-specific Procedures (SSP) manual.

#### **General Information/Instructions:**

A missed visit form will be dynamically added to a visit folder if the response to "Was this visit completed?" on the Follow-up Visit Y/N from is "No". Complete the Missed Visit eCRF only for this visit.

#### **Item-specific Instructions:**

Field	Instructions
Target Visit Date:	Record the target date of the visit based on the participant's Enrollment date. A complete date is required.
Reason visit was missed:	Select the reason that the participant missed the visit from the drop down list. If the reason that the participant missed the visit is not included in this list, select 'other', and specify the reason that the reason was missed in the "If other, specify" text field provided.
Steps taken to address the missed visit (Corrective action plan)	Record the corrective steps that have been taken or will be taken to address the missed visit and help prevent future missed visits.

### *Study Discontinuation*

#### **Purpose:**

This form is used to document a participant's exit from the study (i.e., study termination).

#### **General Instructions:**

This form is present within the Discontinuations folder. Complete this form for each enrolled participant at either the scheduled exit/end of study visit or when the participant is no longer participating in the study.

#### **Item-specific Instructions:**

Field	Instructions
Date of Study Exit	A complete date is required.
Primary reason for completion/discontinuation	Select one reason from the drop-down menu.

<i>If withdrawal of consent by participant, investigator decision, or other, specify</i>	If the primary reason is 'Withdrawal of consent by participant', 'Investigator decision', or 'Other', then provide additional details in the text field provided.
<i>If death, enter date of death</i>	If the primary reason for study discontinuation is 'death', provide the date of death. A complete date is required.
<i>If Adverse Event, select applicable Adverse Event</i>	If the primary reason for study discontinuation is 'Adverse Event' or 'Death', select the applicable Adverse Event from the list of AE's in the drop down menu. In situations where more than one AE is associated with termination, record the AE that most strongly influenced the decision to terminate.

## RING FORMS

### Pharmacy Dispensation


**Purpose:**

This log form is used to collect vaginal ring dispensation information at the site Pharmacy.


**General Instructions:**

Complete this form at the Enrollment Visit for all participants. If a new ring is dispensed to a participant, add and complete a new log line. **This form is completed by pharmacy staff only and is not visible to site clinic staff. Only pharmacists who have been granted this role will be able to view and enter data on this eCRF.**

- Select the applicable PTID as documented on the prescription. The search list can be used to enter the PTID and locate the participant's casebook.



- Navigate to the Pharmacy folder to complete the Pharmacy Dispensation eCRF.



- Complete the Pharmacy Ring Dispensation eCRF and save the form.

CONFIDENTIAL DOCUMENT

**Item-specific Instructions:**

Field	Instructions
Date study product dispensed	Record the day, month, and year study product was dispensed to the participant. A complete date is required. At enrollment, the date should match the randomization/enrollment date on the Randomization eCRF.

***Ring Insertion and Removal*****Purpose:**

This form is used to document participant ring use, as well as any ring insertions or removals that occur during follow-up visits (regularly scheduled or interim).

**General Instructions:**

Complete this form at enrollment and each follow-up visit (regularly scheduled or interim) when a ring is inserted or removed during the visit.

**Item-specific Instructions:**

Field	Instructions
Date of assessment	A complete date is required.
Did the participant have a ring in place at the start of the visit?	Select 'Yes' or 'No'.  If 'No', and a ring was not brought into the clinic, then skip to "Was a ring inserted at this visit?"  If 'No', but a used ring was brought into the clinic not inserted (for example, removed at home and brought to the clinic in a bag), the ring removal items below should be completed.
Was the ring removed at this visit?	Select 'Yes' or 'No'.  If 'No', and a ring was not brought into the clinic, then skip to "Was a ring inserted at this visit?"  If 'No', but a used ring was brought into the clinic not inserted (for example, removed at home and brought to the clinic in a bag), the ring removal items below should be completed.
<i>Date ring was removed</i>	A complete date is required.
<i>Time ring was removed</i>	Record the time in the 24-hour clock.
<i>Who removed the ring?</i>	Select 'Participant' or 'Study staff'.
<i>Reason ring was removed</i>	Select the primary reason the ring was removed from the drop-down menu.  If 'Participant declined study ring use' or 'other' is selected as the primary reason, then specify details in the specify text field provided.
Was the ring properly stored?	Select 'Stored' or 'Not stored'.

Was a ring inserted at this visit?	Select the applicable response from the drop-down menu. If a ring was not inserted at this visit (i.e. "Was a ring inserted at this visit?" = 'No'), then end the form.
<i>Date ring was inserted</i>	A complete date is required.
<i>Time ring was inserted</i>	Record the time in the 24-hour clock.
Who inserted the ring?	Select 'Participant' or 'Study staff'.

## CLINICAL FORMS

### *Physical Exam*

#### **Purpose:**

This form is used to document the participant's physical exam findings.

#### **General Instructions:**

Complete this form at V1.0 - Screening, V2.0 - Enrollment, V11.0 – Day 90, and when clinically indicated during follow-up. If abnormal findings are found for any of the assessments at Screening or Enrollment, enter the information on the **Baseline Medical History Log** (or **Adverse Event Log** at follow-up visits) as applicable.

#### **Item-specific Instructions:**

Field	Instructions
Exam Date:	Enter the date the physical exam was performed. A complete date is required.
Organ Systems or Body Parts Evaluated:	<p>For each organ system or body part evaluated, indicate whether the findings were normal or abnormal. If abnormal, describe the abnormality in the corresponding text field. For any baseline abnormal and clinically significant findings, record the associated condition(s) on the Baseline Medical History Log. Any abnormalities or baseline conditions that worsened during follow-up should be reported on the Adverse Events Log.</p> <p>If an organ system or body part is not evaluated, select 'Not done'. Additional information may also be provided in the text field for why 'Not done', but this is not required.</p> <p>Per protocol, lymph nodes, abdomen, neck, heart, lungs, breast, extremities, skin, and neurological may be omitted during targeted physical examinations</p>

Field	Instructions
Other:	<p>If other systems were assessed not covered by the pre-defined assessments, then please specify whether findings were 'Abnormal' or 'Normal' under the "Other" section. If no other abnormal findings are identified, select 'Not Done'.</p> <p>If another body system was evaluated, specify the body system in the 'Other system, specify' text field.</p> <p>If an 'Abnormal' finding is reported, describe the abnormality in the 'Abnormal', specify' text field.</p>

### *Vital Signs*

#### **Purpose:**

This form is used to document the participant's vital signs.

#### **General Instructions:**

Complete this form at V1.0 - Screening, V2.0 - Enrollment, V11.0 – Day 90, and when clinically indicated during follow-up.

#### **Item-specific Instructions:**

Field	Instructions
Date of Assessment	Enter the date the participant's vital signs were measured. A complete date is required.
Height	Enter the participant's height in centimeters. Per protocol, height is required only at the Screening Visit and can be omitted at all other visits.
Weight	Enter the participant's weight in kilograms. The value can be reported up to one decimal (e.g. 70.1 kg).
Body Temperature	Enter the participant's temperature in Celsius. The value can be reported up to one decimal (e.g. 37.2° C).
Systolic BP*	Enter the participant's systolic blood pressure in mmHg (e.g., 120 mmHg).
Diastolic BP*	Enter the participant's diastolic blood pressure in mmHg (e.g., 60 mmHg).
Pulse	Enter the participant's pulse in beats per minute (e.g., 60 beats/min).
Respirations	Enter the participant's respiratory rate in breaths per minute (e.g., 14 breaths/min).

\* In Medidata Rave, the most recent BP reading that is used for clinical management should be recorded on the Vital Signs eCRF. In instances where the BP has already been entered within Medidata Rave, these fields (Systolic BP and Diastolic BP) can be updated within the form and re-saved.

### *Pelvic Exam*

#### **Purpose:**

CONFIDENTIAL DOCUMENT

This form is used to document the participant's pelvic exam assessment.

**General Instructions:**

Complete this form at V1.0 - Screening, V2.0 - Enrollment, V4.0 – Day 14, V6.0 – Day 30, V7.0 – Day 44, V9.0 – Day 60, V10.0 – Day 74, V11.0 – Day 90, and when clinically indicated during follow-up. Transcribe information from the MTN-044 **Pelvic Exam Diagrams** form or other local site-specific source document into this form for submission in Medidata Rave.

**Item-specific Instructions:**

Field	Instructions
Pelvic exam assessment	If 'not done' is selected, then end of form. Select 'abnormal findings' or 'no abnormal findings' to indicate any findings from the pelvic exam. If 'no abnormal findings' is selected, then skip the "Abnormal findings" section.
Exam Date	A complete date is required.
Abnormal findings	Select the box to the right of each abnormal finding observed, and check all that apply. Specify additional details in the text field provided where applicable.  If an observed abnormal finding is not listed, select "Other abnormal findings" and specify/describe the abnormal findings in the text field provided, including the anatomical location. Record any baseline abnormalities on the Baseline Medical History Log. Any baseline abnormalities that worsened during follow-up should be reported on an Adverse Event eCRF.  In general, for abnormal findings reported as adverse events on an AE Log, use the abnormal finding text provided on this form as the AE descriptive text.
Were any new pelvic finding AEs reported at this visit?	Record whether an AE was identified and reported at this visit as part of the pelvic exam assessment by selecting 'Yes' or 'No'. If an AE was reported at the study visit, select the corresponding AE log form within the dynamic search list function on the eCRF. Up to three AEs can be selected.  This item should be marked 'No' prior to participant enrollment in the study (i.e., prior to the AE reporting period).
Cervical Ectopy	Select the percentage of cervical ectopy observed during the pelvic exam assessment by selecting the appropriate drop down option within the eCRF.  Select 'Not assessed' if cervical ectopy was not assessed.

***Pelvic Exam Diagrams Form***

**Purpose:**

This form can be used to document all variants of normal and all abnormal findings observed during study pelvic exams.

**General Information/Instructions:**

CONFIDENTIAL DOCUMENT

Complete this form at V1.0 - Screening, V2.0 - Enrollment, V4.0 – Day 14, V6.0 – Day 30, V7.0 – Day 44, V9.0 – Day 60, V10.0 – Day 74, V11.0 – Day 90, and when clinically indicated during follow-up. Transcribe information onto the appropriate Pelvic Exam CRF and store this form in the participant’s chart notes. This form is available to download and print on the MTN-044 Atlas webpage under the Case Report Forms section within the “Other Documents” section. Please refer to the back of the form for specific guidelines on completing this form.

### ***Baseline Medical History Y/N***

**Purpose:**

To document any baseline medical history conditions/events reported at the Screening visit or recalled by the participant at Enrollment.

**General Instructions:**

This prompt will be asked at the V1.0 – Screening visit. (Note that this form is not present within the “Ongoing Logs” folder).

**Item-specific Instructions:**

Field	Instructions
Does the participant have any medical history to report?	<p>Select ‘Yes’ or ‘No’.</p> <p>If ‘Yes’ is marked, then the “Baseline Medical History Log” form appears dynamically within the V1.0 – Screening visit folder. Complete entries within the Baseline Medical History Log eCRF as needed.</p> <p>If ‘No’ is selected, no further action is required.</p> <p>If the participant reports any baseline medical history conditions/events at the Enrollment visit, update the response to this field to ‘Yes’ and complete the Baseline Medical History Log as needed.</p>

### ***Baseline Medical History Log***

**Purpose:**

This form is used to document information on the participant’s baseline medical history, including but not limited to: history of hospitalizations, surgeries, allergies, any condition that required prescription or chronic medication (that is, more than 2 weeks in duration), and acute conditions ongoing at screening and/or that occur between screening and enrollment.

This form will appear in the V1.0 - Screening folder after the “Baseline Medical History Summary” prompt has been answered as ‘Yes’. Use the “Add a new Log line” button to add an additional baseline medical history condition/event in Medidata Rave.

**General Instructions:**

CONFIDENTIAL DOCUMENT

- At the Screening Visit, record relevant baseline medical history. This includes conditions and symptoms reported by the participant during the baseline medical/menstrual history as well as any conditions identified via pelvic exam, physical exam, or laboratory testing.
- At the Enrollment Visit, review and update as needed. Navigate back to the V1.0 – Screening visit folder to update this log form if needed or add additional entries as needed. Those conditions that are ongoing at the time of enrollment (including ongoing chronic conditions) are considered the participant’s pre-existing conditions.
- If a medical condition increases in severity or frequency during follow-up and is captured as an AE, the medical history **should not** be updated to include an End Date.
- Do record baseline medical conditions identified during follow-up. Write a chart note to explain why the entry was added after the Enrollment Visit.
- Complete a separate entry (e.g. log line) for each baseline medical history condition/event when entering into the study database.

**Item-specific Instructions:**

Field	Instructions
Date medical history collected	Record the date the medical history condition/event was reported by the participant. A complete date is required.
Description of medical history condition/event	Whenever possible, provide a diagnosis instead of listing a cluster of symptoms. If no diagnosis is identified, each symptom must be recorded as a separate term. If an abnormal lab value is reported at the Enrollment visit, record the lab assay with the direction (i.e., increased or decreased) of the abnormality. For example, “decreased hematocrit” or “increased ALT”.  Additional information on the frequency and duration of chronic condition outbreaks can also be provided within this description.
Is condition/event gradable?	If a condition is not gradable (below Grade 1), select ‘No’. Review and update as needed for conditions that are ongoing during the study.  If a condition is gradable, select ‘Yes’ and complete the Severity Grade.

Field	Instructions
Severity Grade	<p>This item is required if 'Is condition/event gradable?' is 'Yes'.</p> <p>Select from the options provided in the drop-down list.</p> <p>Review and update as needed for conditions ongoing at the Enrollment Visit. The toxicity grade reported in Baseline Medical History should reflect the status at baseline.</p> <ul style="list-style-type: none"> <li>• If the severity grade has increased or decreased in severity or frequency during the study AE reporting period, then this should be reported as an AE and the Toxicity Grade should remain unchanged on this CRF. However, this should be updated as needed if the severity grade and increased or decreased on or prior to the Enrollment Visit.</li> <li>• If the item improves severity or resolves during the study, then the Toxicity Grade should remain unchanged on this CRF.</li> </ul> <p>For each condition, grade the severity using the current version of the <i>Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events</i> (including relevant appendices/addendums).</p>
Start Date of medical history condition/event	<p>Record the date the medical condition was first diagnosed or the date the surgery/procedure was performed as applicable. If the participant is unable to recall the exact date, obtain her best estimate. At a minimum, a year is required.</p> <p>If the exact day is unknown, enter 'UN' for the day field. If the exact month is unknown, then select 'UNK' for the month field. For example, a partial date may be recorded as: UN-Jan-2010 or UN-UNK-2010.</p>
Is the condition ongoing?	<p>Select 'Yes' for chronic conditions, as well as any other conditions that are currently ongoing.</p> <p>During each follow-up visit, routinely follow-up on any and all ongoing conditions. If the condition resolves during follow-up, this item should not be updated.</p> <p>If this item is selected 'Yes', then this is the end of form and the "Date medical condition/event ended/resolved" should be left blank.</p>

Field	Instructions
Date medical history/condition ended/resolved	<p>A date is required if required if 'Is the condition ongoing?' is 'No'. If the exact day is unknown, enter 'UN' for the day field. If the exact month is unknown, then select 'UNK' for the month field. At a minimum, a year is required.</p> <p>Record the date the medical condition was considered resolved. For surgeries/procedures, record the date the surgery/procedure was conducted.</p> <p>If a condition resolves during the study, the Baseline Medical History form should <b>not</b> be updated with a resolution or end date for the medical condition.</p>

### Adverse Events Y/N

**Purpose:**


This form documents if an adverse event was experienced by the participant during the study.

**General Instructions:**

This form is located within the "Ongoing Logs" folder.

**Item-specific Instructions:**

Field	Instructions
Has the participant experienced an Adverse Event during the study?	<p>Select 'Yes' or 'No'.</p> <p>Within the "Ongoing Logs" folder, if 'Yes' is selected, then the "Adverse Event" log form appears dynamically and can then be completed. Complete one Adverse Event eCRF for each AE reported during the AE reporting period.</p>



### Adverse Event Log

**Purpose:**

To document any Adverse Event (AE) reported by the participant or clinically observed as defined by the protocol.

CONFIDENTIAL DOCUMENT

**General Instructions:**

Complete a separate AE log form for each adverse event when entering into the study database. Use the “Add a new Log line” button to add an additional adverse event in Medidata Rave.

Whenever possible, report a diagnosis instead of listing a cluster of symptoms. If no diagnosis is identified, each symptom must be recorded as a separate AE log page as applicable. If a cluster of symptoms reported on separate AE Log pages is later attributed to a single diagnosis, update the earliest reported symptom page to the diagnosis. In the study database, the remaining symptoms can be deleted by clicking “Inactivate” and selecting the applicable rows that should be inactivated.

A baseline medical condition should only be recorded as an AE during follow if the condition increases in frequency and/or severity.

If an AE increases in severity/frequency, a new AE should be reported. The original AE should be marked “Recovered/resolved” with an Outcome Date equal to the Onset Date of the new AE. Note that decreases in severity (AE improvements) are not recorded as new AEs.

**Item-specific Instructions:**

Field	Instructions
Date Reported to Site	Record the date the site became aware of the AE. For lab AEs, record the date the lab result was received. A complete date is required.
Adverse Event (AE)	Use medical terminology to describe the AE. Record a diagnosis if available. Include the anatomical location if applicable. Do not include text regarding the relationship to study product or timing of AE onset with regard to product use. For lab abnormalities, record the lab name with the direction (i.e., increased or decreased). For example, “increased ALT”.
Onset Date	At a minimum, a month and year are required.  Record one of the following, as appropriate: the date on which the participant reports first experiencing the AE (onset of first symptom if diagnosis has multiple associated symptoms); date of the study visit/study exam (for physical or pelvic exam findings); specimen collection date (for lab abnormality AEs).
At which visit was this AE first reported?	Select the visit at which the AE was first reported from the drop down menu. If the AE was reported at an interim visit, select “interim visit” and enter the interim visit code in the text field provided.
Is the AE still ongoing?	Select ‘Yes’ if the AE is continuing at the time it is first reported. If ‘Yes’, leave the Outcome Date blank.
Outcome Date	If the AE is not ongoing, record the outcome date. For the Outcome Date, a month and year are required, at a minimum.  Record one of the following, as appropriate: the date on which the participant reports no longer experiencing the AE or associated symptoms, or the date of the study visit or specimen collection at which it is first noted the AE has resolved or returned to baseline status.

Field	Instructions
Severity Grade	Record the severity grade using the current version of the <i>Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events</i> (including relevant appendices/addendums).
Relationship to Study Product	Select 'related' if there is a reasonable possibility that the AE may be related to the study agent. Select 'not related' if there is not a reasonable possibility that the AE is related to the study agent. Provide the clinical rationale (the reason) the AE is judged to be 'related' or 'not related' in the Comments section/text field provided.
Action Taken with Study Product	<p><b><i>Dose not changed:</i></b> Select if there is no change to the participant's planned use of study product as a result of the AE. This option should be marked if the participant is still in the product use period and the AE does not result in a clinician-initiated product hold or permanent discontinuation of study product.</p> <p><b><i>Dose reduced:</i></b> This option does not apply and should not be selected in MTN-044.</p> <p><b><i>Dose increased:</i></b> This option does not apply and should not be selected in MTN-044.</p> <p><b><i>Drug withdrawn:</i></b> Select if the AE results in permanent discontinuation of study product. If multiple AEs are reported at the same visit, mark "drug withdrawn" for each AE contributing to the permanent discontinuation.</p> <p><b><i>Drug interrupted:</i></b> Select if the AE results in a clinician-initiated product hold. If multiple AEs are reported at the same visit, select 'drug interrupted' for each AE contributing to the hold. Complete a Product Hold log form for each AE that results in a clinician-initiated product hold.</p> <p><b><i>Not applicable:</i></b> Select if the AE's onset date is on or after the date the participant permanently discontinues study product use.</p>
Other action(s) taken	<p>Select 'None' or check all that apply.</p> <p>Select 'Medication' only if the participant reports taking the medication. Report the medication(s) on the Concomitant Medications Log . If a medication is indicated, but not yet used, select 'Other' and describe the medication indicated in the "Other, specify" text field provided; update this item to 'Medication' once the medication has been used and report on the Concomitant Medications Log.</p> <p>If "New/prolonged hospitalization", "Therapeutic procedure/surgery", or "Diagnostic procedure" is selected, then record applicable details in the Comments section at the bottom of the eCRF.</p> <p>If 'Other', then specify relevant details in the "Other, specify" text field provided.</p>

Field	Instructions
Status/Outcome	<p><b>Recovered/resolved:</b> AE is no longer present, has returned to baseline severity/frequency, or has increased in severity/frequency. Note that if a participant started taking medication once enrolled to control an AE, the AE is not considered resolved while the medication is still indicated.</p> <p><b>Recovering/resolving:</b> AE is continuing and has not yet resolved or returned to baseline severity/frequency.</p> <p><b>Resolved/resolved with sequelae:</b> Participant has recovered from the AE, but with remaining effects or impairment. These remaining effects can be temporary, but are still present at the time of the report.</p> <p><b>Not recovered/resolved:</b> Select this option whenever an AE is continuing at the time of participant termination from the study.</p> <p><b>Fatal:</b> Select only if the severity grade of this AE is Grade 5. Any other AEs continuing at the time of death should be changed to “not recovered/resolved”.</p>
Is this a serious adverse event according to ICH/GCP or protocol guidelines?	<p>If ‘Yes’, complete the following: Initial Reporter; check all that apply of ‘Results in death’, ‘Is life-threatening’, ‘Requires inpatient hospitalization or prolongation of existing hospitalization’, ‘Results in persistent or significant disability/incapacity’, ‘Is a congenital anomaly/birth defect’, and ‘Is another serious important medical event that may jeopardize the patient or require intervention to prevent one of the other outcomes listed above’; ‘SAE narrative’; and ‘Source Document’. If applicable, complete ‘Date study product temporarily interrupted’, ‘Date study product was restarted’, and ‘Date study product permanently stopped’.</p> <p>If ‘No’, skip to ‘Was this AE a worsening of a baseline medical condition?’</p>
Was this AE a worsening of a baseline medical condition?	Select ‘Yes’ or ‘No’.
Comments	This is a required field and should be used to be record the relationship to study product at a minimum.

### ***Concomitant Medications Y/N***

#### **Purpose:**

This form documents if any concomitant medications were reported the participant during the study.

#### **General Instructions:**

This summary eCRF is located within the “Ongoing Logs” folder.

#### **Item-specific Instructions:**

Field	Instructions
Were any concomitant medications taken?	Select ‘Yes’ or ‘No’.

	If 'Yes' is selected, then the "Concomitant Medications Log" form appears dynamically within the "Ongoing Logs" folder and complete as many Concomitant Medication Log eCRFs as needed.
--	---

### ***Concomitant Medications Log***

#### **Purpose:**

This form is used to document all medications taken by the participant starting at the Screening Visit. This includes, but is not limited to: prescription medications, non-prescription (i.e., over-the-counter) medications, contraceptive hormonal medications, preventive medications and treatments (e.g., allergy shots, flu shots, and other vaccinations), herbal preparations, vitamin supplements, and naturopathic preparations.

#### **General Instructions:**

Complete a separate log form for each reported concomitant medication. Use the "Add a new Log line" button to add an additional concomitant medication in Medidata Rave.

#### **Item-specific Instructions:**

<b>Field</b>	<b>Instructions</b>
Medication Name	Record the trade or generic name of the medication based on exactly what the participant is taking. If a trade name is not available or not reportable per national guidelines, record the generic name of the medication. A combination medication can be recorded as one entry.
Indication	For health supplements, such as multivitamins, record 'general health'. For preventive medications, record 'prevention of [insert condition]' (e.g., for flu shot, record "prevention of influenza"). In most instances (excluding nutritional supplements and/or prophylactic treatments), the indication should correspond to an item on the Baseline Medical History and/or Adverse Event eCRF(s).
Date Started	If the participant is unable to recall the exact date of medication initiation, obtain participant's best estimate. At a minimum, the year is required. For injections, record each injection as a separate entry, with the same date used for start and stop date.
Date stopped	Enter the stop date of this medication if known. At a minimum, the month and year is required. This item can be completed at any time during study participation when the stop date is known. At the participant's Study Exit/Termination Visit, the "Date Stopped" must be recorded for each medication OR the "Or, continuing at end of study" box must be checked.

Dose	<p>Record the dose. If the participant does not know the exact dose units (e.g., “250 mg”), record an estimate (e.g., “1 tablet”).</p> <p>If the dose of each ingredient of a combination drug is provided separately, document each active ingredient as a separate log entry. For example, record the use of hydrocodone/acetaminophen 5/500 as two separate log entries – one log form for the hydrocodone and a second log form for acetaminophen.</p> <p>For multivitamin tablets or liquids, record the number of tablets or liquid measurement (e.g. “1” pill or “1” tablespoon”) if the exact dosage is unknown.</p> <p>If the dose is unknown select the “Dose Unknown” checkbox and leave the Dose field blank.</p> <p>When documenting medical devices with no active medication, such as an IUCD, enter the dose as “1”.</p>
Dose Units	<p>Select/record the applicable dose units provided in the drop-down list.</p> <p>If the participant does not know the exact dose units (e.g., “250 mg”), record an estimate (e.g., “1 tablet”).</p> <p>If no information on units is known, select the ‘Unknown’ option.</p> <p>When documenting medical devices with no active medication, such as an IUCD, mark the Dose Unit as ‘Other’ and specify “device” in the “If other dose units, specify” text field provided.</p>
Frequency	<p>Select the frequency from options provided in the drop-down list.</p> <p>Below is a list of common frequency abbreviations:</p> <p>PRN: as needed  QD: every day  BID: twice daily  TID: three times daily  QID: four times daily  QM: every month  QH: every hour  ONCE: one time</p> <p>Other: alternative dosing schedule or unknown If ‘Other’ is selected, specify in the corresponding “If other frequency, specify” text field provided.</p>

Route	<p>Select the route from options provided in the drop-down list.</p> <p>Below is a list of common route abbreviations:</p> <p>PO: oral  IM: intramuscular  IV: intravenous  TOP: topical  IHL: inhalation  VAG: vaginal  REC: rectal  SC: subcutaneous  Other: alternative routes or unknown</p> <p>If 'Other' is selected, specify in the corresponding "If other route, specify" text field provided.</p>
Taken for a reported AE?	<p>If the concomitant medication was administered to treat a reported AE, select 'Yes'. The relevant AE log form must be completed to link the concomitant medication to the AE log form entered. Choose the applicable AE from the drop-down list. Up to four AEs can be selected. If the medication was not administered to treat an AE, select 'No', and end the form.</p>

### ***Product Hold Summary***

#### **Purpose:**

This form documents if a clinician-initiated product hold was applied during the study.

#### **General Instructions:**

This form is present within the "Ongoing Logs" folder. Selecting 'Yes' in the "Does the participant have any clinical product holds to be applied?" prompt will add the "Clinical Product Hold" log to the "Ongoing Logs" folder.

### ***Product Hold Log***

#### **Purpose:**

This form is used to document temporary clinical holds of study product use as instructed by study site staff.

#### **General Instructions:**

This form is completed each time a participant is instructed by study staff to temporarily stop (hold) study product use. If, at the same visit, a product hold is initiated for more than one reason, complete one Product Hold log line for each reason. To add an additional Clinical Product Hold log line within Medidata Rave, click "Add a new Log line" to add an additional log line for a new product hold to be completed.

Complete this form for any clinical reason that warrants a product hold regardless of whether participants choose to use the ring or who choose to not use study product during the study. Do not complete this form in cases where a participant has decided herself to not use the study vaginal ring.

#### **Item-specific Instructions:**

**CONFIDENTIAL DOCUMENT**

Field	Instructions
Date when study product hold was initiated:	Record the date when the product hold was initiated or would have been initiated in instances where the participant has chosen not to use the ring. A complete date is required.
Why is study product being held?	Record the reason that study product is being held.  If study product is held for any reason not specified, mark "Other, specify" and specify the reason in the space provided. Note that participant decline or refusal of study product is not documented as a product hold. Do not record this as a reason in "other, specify".
Adverse Event	If study product is being held due to "Adverse Event", select the applicable AE from the drop-down field provided.  <b>Note:</b> If study product is being held due to an AE, the AE log page must be entered into Rave prior to completion of the Clinical Product Hold log form in order for the AE to be available to select with the drop down field.
Concomitant Medication	If study product is being held due to "Reported use prohibited medications", specify the corresponding concomitant medications log form on which the medication was reported in from the drop down field provided with Rave. At least one medication must be specified and up to four medications can be recorded.  <b>Note:</b> If the product hold is due to report of medication use, the corresponding concomitant medications log page must be entered into Rave prior to completion of the Product Hold log form in order the medication be to be available within the drop down field.
Date of last study product use	Record the last date the study product was present in the vagina. Use a best estimate if the actual date cannot be determined.

<p>Was the participant instructed to resume study product use?</p>	<p>Mark, “No – hold continuing for another reason” if the participant would have been instructed to resume study product based on the resolution of the reason indicated on this form. If ‘No – hold continuing for another reason’, enter below the ‘date study product hold continuing for another reason’.</p> <p>Mark, “No – early termination” if the product hold was ongoing at the visit at which the participant terminated early from the study.</p> <p>Mark, “No – hold continuing at scheduled PUEV” if the product hold was ongoing at time of the participant’s scheduled Product Use End Visit.</p> <p>Mark, “No – permanently discontinued” if the participant was permanently discontinued from study product due the reason indicated on this form.</p> <p>If ‘yes’, enter below the date that the participant was instructed to resume study product.</p> <p><u>If 'no - permanently discontinued', 'no - early termination' or 'no - hold continuing at scheduled PUEV', complete the Product Discontinuation form.</u></p>
--	---


***Product Discontinuation***

**Purpose:**

This form documents a participant’s permanent discontinuation of study product use.

**General Instructions:**

This form is present within the “Discontinuations” folder. Complete this form for each enrolled participant when study product use is permanently discontinued.



**Item-specific Instructions:**

Field	Instructions
Date that study product use ended	A complete date is required. Record the date when the participant completed or was permanently discontinued from study product.
Primary reason for ending study product use	Record the primary reason from the drop-down menu.  If ‘Scheduled study product use period completed’, then end the form.  If ‘Adverse Event’ is selected, specify the AE entry from the AE dynamic drop-down list.

	<p><b>Note:</b> If study product is permanently discontinued due to an AE or allergic reaction to the vaginal ring, the AE log page must be entered into Rave prior to linking the AE on the Product Discontinuation eCRF in order for the AE to be available to select with the drop down field.</p> <p>If the primary reason is “Other”, provide additional details in the “If other, specify” text field provided.</p>
--	---

### *Pregnancy Report*


**Purpose:**

Complete this form when reporting a pregnancy of a study participant post enrollment through study discontinuation.

**General Instructions:**

A Pregnancy Report form is required for each new pregnancy that the participant experiences during the study.

To complete a Pregnancy Report form within Medidata Rave, use the Add Event dropdown menu on the participant’s home page to add a Pregnancy folder. This will add a Pregnancy folder to the participant’s case book. The Pregnancy folder will contain the Pregnancy Report and Pregnancy Outcome Log eCRFs.



**Item-specific Instructions:**

Field	Instructions
First day of last menstrual period	A complete date is required. Record best estimate if date not known. If the participant is amenorrheic, select the checkbox for item ‘Amenorrheic for past 6 months’ and leave the First day of last menstrual period date fields blank.
Estimated due date	A complete date is required.
Method used to determine due date	Choose the primary method that was used to estimate the date of delivery. If another method was used which are not covered by the currently listed methods, please select ‘Yes’ for “Other” and describe them in the ‘If other, specify’ text field provided.
Estimated date of conception (based on estimated due date)	A complete date is required.

## *Pregnancy History*

### **Purpose:**

Complete this form for all study participants to document any previous pregnancies.

### **General Instructions:**

This form is completed at the Screening Visit. Complete this form for all study participants.

### **Item-specific Instructions:**

Field	Instructions
Has the participant ever been pregnant before?	<p>If the participant has never been pregnant before, select “No” and end the form.</p> <p>If ‘yes’, an entry is required for each of the following: How many times has the participant been pregnant, Date last pregnancy ended, Number of full term live births (&gt;=37 weeks), Number of premature live births (less than 37 weeks), Number of vaginal births, Number of c-section births, Number of spontaneous fetal deaths and/or still births (&gt;=20 weeks), Number of spontaneous abortions (less than 20 weeks), Number of therapeutic/elective abortions, Number of ectopic pregnancies. Enter ‘0’ for any that do not apply.</p>
Does the participant have a history of pregnancy complications or fetal/infant congenital anomalies?	<p>If the participant does not have a history of pregnancy complications, select ‘No’ and end the form.</p> <p>If “Yes”, then include information on pregnancy complications and fetal/infant congenital anomalies experienced prior to enrolling in the study as well as any conditions experienced/reported during the study in the corresponding text field provided.</p>

## *Pregnancy Outcome Log*

### **Purpose:**

This form is used to report pregnancy outcome information for a pregnancy reported post-enrollment. A Pregnancy Outcome Log line must be completed for each pregnancy reported during the study.

### **General Instructions:**

This form will be in the Pregnancy folder of a participant’s casebook. To add another outcome, click “Add a new Log line”.

### **Item-specific Instructions:**

Field	Instructions
Is the outcome of this pregnancy obtainable?	<p>If site staff were able to ascertain an outcome for this pregnancy from the participant, select “Yes”.</p> <p>If site staff were not able to ascertain an outcome for this pregnancy from the participant (i.e. the participant refuses further contact), select “No” and end the form.</p>

CONFIDENTIAL DOCUMENT

Field	Instructions
How many pregnancy outcomes resulted from this reported pregnancy?	If the pregnancy results in two or more outcomes, complete a new log line for each outcome. If the item is completed as greater than "1", add additional log lines to the Pregnancy Outcome Log eCRF, as needed.
Outcome Date	A complete date is required.
Place of delivery/outcome	Enter the place of delivery/outcome from the drop-down menu. If 'Other' is selected, specify in the corresponding "Other, specify" text field.
Specify Outcome	Specify the outcome from the drop-down menu. If the outcome is stillbirth, spontaneous abortion, therapeutic/elective abortion, or ectopic pregnancy, the outcome itself is not an adverse event (AE). If a therapeutic/elective abortion is performed due to a pregnancy complication, the pregnancy complication should be reported on an Adverse Event (AE) Log, if prior to termination, with 'therapeutic procedure/surgery' checked for item "Other action(s) taken". If there are any maternal complications as a result of the pregnancy outcome, refer to the protocol, Study-specific Procedures (SSP) manual, and <i>Manual for Expedited Reporting of Adverse Events to DAIDS, Version 2</i> for guidance on AE and expedited AE reporting requirements.  If 'other' is selected, specify in the corresponding "If Other, specify" text field.
Method	Select the method from the drop-down menu only if the outcome is 'full term live birth ( ≥37 weeks)' or 'premature term live birth (< 37 weeks)'. "Operative Vaginal" delivery includes delivery with forceps and/or vacuum.  If the outcome is 'full term live birth', skip to "Were there any complications related to the pregnancy outcome?"
Provide a brief narrative of the circumstances	Include information on medical conditions associated with the outcome, including early contractions, rupture of membranes, and cramping, along with actions taken as a result of these conditions. This item is only required if <b>not</b> a full term live birth.
Were there any complications related to the pregnancy outcome?	Select 'yes' or 'no' to indicate if there were any complications related to the pregnancy outcome. If 'no', then items "Delivery-related complications" and "Non-delivery related complications" are not required.
Delivery-related complications	Select 'None' or check all that apply. If 'other' is selected, specify in the corresponding "If Other, specify" text field.
Non-delivery related complications	Select 'None' or check all that apply. If 'other' is selected, specify in the corresponding "Other, specify" text field.
Were any fetal/infant congenital anomalies identified?	Record if any fetal/infant congenital anomalies were identified. If "No" or "Unknown", go to statement "Complete the infant items below for live births only" above "Infant Gender".

CONFIDENTIAL DOCUMENT

Field	Instructions
Congenital anomalies identified.	<p>If there were fetal/infant congenital anomalies identified, then check all that apply.</p> <p>If a woman on study has a baby with a congenital anomaly, report the event on an Adverse Event (AE) Log eCRF, if prior to study discontinuation. On the AE Log eCRF, record "Congenital Anomaly in Offspring" in the AE description, record the Outcome Date as the Onset Date, and record the specific anomaly in the Comment Section. Submit an Expedited Adverse Event (EAE) Reporting form.</p>
Describe the congenital anomaly/defect	Describe the congenital anomaly/defect in the text field provided.
Infant items	Complete the infant items for live births only. Otherwise, end the form.
<i>Infant Gender, Infant birth weight, Infant birth length, Infant birth head circumference, Infant birth abdominal circumference</i>	Complete these items for live births only. Record the information as documented in medical records. If no medical record documentation of the information is available, complete this item based on participant report. Check the "unavailable" box if no medical record documentation is available and the participant does not know the information.
<i>Infant Gestational age by examination in weeks</i>	Record the infant's gestational age at birth. If the infant's gestational age is determined using the Ballard method, record "0" in the "days" box. Check the "unavailable" box if no medical record documentation of the infant's gestational age is available and end the form. If an 'other' method is selected for "Method used to determine gestational age", specify in the corresponding "If other, specify" text field.

### Screening Menstrual History

#### Purpose:

This form is used to document information on the participant's menstrual history, including menstrual-related symptoms and abnormal bleeding patterns.

#### General Instructions:

Complete this form at the V1.0 - Screening Visit. Please record any baseline abnormalities (e.g. abnormal bleeding patterns such as amenorrhea, menorrhagia, metrorrhagia or menstrual symptoms which contribute to a medical condition (e.g. dysmenorrhea, pre-menstrual syndrome) on the Baseline Medical History Log eCRF. Site staff should carefully consider any abnormal bleeding patterns since participants must have regular menstrual cycles of approximately 21-35 days' duration to be eligible for study participation.

#### Item-specific Instructions:

Field	Instructions
Date medical history collected	Record the date the medical history condition/event was reported by the participant. A complete date is required.

CONFIDENTIAL DOCUMENT

Age of first menses (menarche)	Record the age the participant first started her menses.
In the past 3 months, has the participant had her menses?	Select 'Yes' or 'No'. Note that per protocol, a participant must have <i>regular menstrual cycles</i> of approximately 21 to 35 days' duration to be eligible for the study.
Does the participant typically experience any premenstrual symptoms?	Select 'Yes' or 'No'. If 'yes', specify the types of symptoms the participant typically experiences in the "If yes, specify" text field provided. Include the severity and duration of each symptom.
Usual number of days between menses (1 <sup>st</sup> day to 1 <sup>st</sup> day)	Record the usual number of days that the participant experiences between menses, starting on the first day of her menstrual period up to and including the day before the first day of her next menstrual period. Per protocol, a participant must have regular menstrual cycles of approximately 21 to 35 days' duration to be eligible for the study.
For how many days does the participant usually experience bleeding?	Record the average number of the usual number of bleeding days of the participant's menses.
Minimum and maximum usual number of bleeding days	Record the range (minimum and maximum) of the usual number of bleeding days of the participant's menses.
Provide additional details as needed to describe the participant's baseline menstrual bleeding pattern.	During follow-up, occurrences of genital bleeding will be compared to the participant's baseline bleeding pattern, as documented on this form. With this in mind, use the text field to describe, as best as possible, any additional details on the participant's usual genital bleeding pattern. Include details such as the number of sanitary pads typically used, any spotting that is experienced, and any additional details on amount/heaviness of flow. Note that up to 400 characters are allowed in this field.
First day of last menstrual period	Record the first day of the participant's most recent menstrual period. At a minimum, the month and year are required.
Last day of menstrual period	Enter the last day of the last menstrual period (last day of bleeding). At a minimum, the month and year are required. If the participant is currently on her menses, check "Ongoing" and leave the last day of last menstrual period blank. After the Enrollment Visit, this item does not need to be updated with a stop date once known. Ideally, menses must not coincide with the 14 days of product use.
The last time the participant had her menses, was the bleeding light, moderate or heavy?	This item is based on how the participant describes her heaviest flow day during menses. Select the participant's response from the drop-down list.

### ***Enrollment Menstrual History***

#### **Purpose:**

This form is used to document information on the participant's menstrual history since the Screening Visit.

#### **General Instructions:**

Complete this form at the V2.0 – Enrollment Visit.

CONFIDENTIAL DOCUMENT

**Item-specific Instructions:**

Field	Instructions
Date of assessment	Record the date the menstrual history was reported by the participant. A complete date is required.
Since the Screening Visit, has the participant had her menses?	Select 'Yes' or 'No'. Ideally, menses must not coincide with the 14 days of product use.
First day of last menstrual period	Record the first day of the participant's most recent menstrual period. A complete date is required.
Last day of menstrual period	Enter the last day of the last menstrual period (last day of bleeding). A complete date is required. If the participant is currently on her menses, check "Ongoing" and leave the last day of last menstrual period blank. Ideally, menses must not coincide with the 14 days of product use.

***Vaginal Bleeding Assessment*****Purpose:**

This form is used to document additional information about any spotting/bleeding, as well as the site study clinician's assessment of the bleeding/spotting, if any.

**General Instructions:**

This form will be dynamically added, and is required to be completed, if any bleeding is reported on the Bleeding SMS eCRF. This form will not be completed if bleeding is not reported on the Bleeding SMS eCRF.

**Item-specific Instructions:**

Field	Instructions
Date of assessment	A complete date is required.
Did the participant continue ring use during any spotting/bleeding episodes?	Select 'Yes' if she continued ring use during any of the spotting/bleeding reported on the Bleeding SMS form in the same visit folder.
Did the participant use tampons during any spotting/bleeding episodes?	Select 'Yes' if she used tampons during any of the spotting/bleeding reported on the Bleeding SMS form in the same visit folder.

According to the participant, did any spotting/bleeding occur within 2 days after: <i>Vaginal sex, painful vaginal sex, painful or uncomfortable insertion or removal of the ring, painful or uncomfortable insertion or removal of any other vaginal product/preparation, a Pelvic exam, Condom use?</i>	Select 'Yes' or 'No'. If 'Yes' to any item(s), record any additional relevant details in the corresponding "If yes, record any relevant details" text field. If "A pelvic exam" is 'Yes', record the date of the last pelvic exam in the corresponding text field.
Based on all information available, is this bleeding menstrual or non-menstrual?	Select the appropriate option from the drop-down list. Select 'Unknown' if this information cannot be determined.
Is this bleeding/spotting an SAE?	If 'Yes' is selected, select the AE CRF from the dynamic drop-down list. Please note that the AE will need to be entered prior to linking.

## LABORATORY FORMS

Please remember to record clinically significant laboratory results on the "Baseline Medical History Log" eCRF or "Adverse Event Log" eCRF as applicable.

- Clinically significant laboratory results do NOT have to be reported as an AE if the lab result is clinically significant due to an indication in the subject's medical history.
- If the clinically significant laboratory result is already recorded in the baseline medical history but has increased in severity, frequency, or character, it should be recorded as an AE.

### *HIV Test Results*

#### **Purpose:**

This form is used to document HIV rapid test results from local lab HIV testing.

#### **General Instructions:**

Complete this form at V1.0 – Screening, V2.0 – Enrollment, V11.0 – Day 90, and as indicated during follow-up.

#### **Item-specific Instructions:**

Field	Instructions
Was Sample 1 collected for HIV Testing?	Select 'Yes' or 'No'.  If 'No', end of form

Field	Instructions
Date of collection	Record the date that the first specimen(s) was collected, NOT the date the results were reported or recorded on the form for this visit. A complete date is required.
Sample 1 HIV test result	If the Rapid test is positive or indeterminate, complete the HIV Confirmatory Test Result form and alert the MTN Laboratory Core.

### *HIV Confirmatory Tests*

#### **Purpose:**

This form is used to document HIV confirmatory results from local lab confirmatory HIV testing.

#### **General Instructions:**

This form will be dynamically added if 'positive' or 'indeterminate' is selected on the HIV Test Results eCRF.

#### **Item-specific Instructions:**

Field	Instructions
Was HIV confirmatory testing done for sample 1?	Select 'Yes' or 'No'.
Date confirmatory testing for sample 1	Record the date that the first specimen(s) was collected, NOT the date the results were reported or recorded on the form for this visit. A complete date is required.
Sample 1 HIV Confirmatory test result	If the Sample 1 HIV Confirmatory test result is negative, indeterminate, or invalid, contact the MTN Virology Core.  If positive at a follow up visit, collect sample 2 and plasma for testing by the MTN Virology Core.
Was sample 2 collected for HIV Confirmatory testing (by MTN Virology core)?	Select 'Yes' or 'No'. If Sample 2 was collected, complete the remaining items.
Collection Date	Record the date that the first specimen(s) was collected, NOT the date the results were reported or recorded on the form for this visit. A complete date is required.
Sample 2 HIV confirmatory test result	Select 'Positive', 'Negative', or 'Indeterminate'.
Was a sample for testing by the MTN Virology Core stored?	Select 'Yes' or 'No'.
Final HIV Status	Once a participant's HIV status has been determined, record the final HIV status from the drop-down menu. If the participant's final HIV status is determined to be positive (according to the protocol testing algorithm), update the Product Discontinuation to reflect permanent discontinuation of study product. If the participant status is not clearly negative or clearly positive, select the 'pending' item and update this item once the participant's final HIV status is known.

## STI Test Results

### Purpose:

This form is used to document STI test results performed by the local site laboratory.

### General Instructions:

Complete this form at the V1.0 - Screening Visit and as indicated during the study.

If any or all of the lab tests listed on this form are repeated (re-drawn) between the Screening and Enrollment Visit, document the repeated results on the same STI Results form. If the participant enrolls, the updated results should be submitted into the study database.

At Screening, record STI diagnoses in Baseline Medical Conditions Log form when applicable.

### Item-specific Instructions:

Field	Instructions
Was vaginal pH done?	Select 'Yes' or 'No'.  If 'No', skip to 'Was a vaginal wet prep sample collected?'
Date of collection	Record the date that the specimen was collected, NOT the date the results were reported or recorded on the form for this visit. A complete date is required.
Vaginal pH	Record the vaginal pH (e.g., 4.1).
Was a vaginal wet prep sample collected?	If "Vaginal wet prep" was not done or not collected, select the 'No' option for "Was a vaginal wet prep sample collected?", do not complete the "Date of collection" or corresponding test results, and skip to 'Was a sample collected for Syphilis testing?'  If a vaginal wet prep was performed but not all assays were completed, select "Not done" for each uncompleted wet prep assay.
Date of collection	Record the date that the first specimen(s) was collected, NOT the date the results were reported or recorded on the form for this visit. A complete date is required.
<i>Homogenous vaginal discharge</i>	Select 'Positive' if homogeneous vaginal discharge was observed.
<i>Whiff test</i>	Select 'Positive' if a fishy, amine odor is detected.
<i>Clue Cells greater or equal to 20%</i>	Select 'Positive' if 20% or more of the cells were clue cells.
<i>Trichomonas vaginalis</i>	Select 'Positive' if trichomonas were observed.
<i>Buds and/or hyphae (yeast)</i>	Select 'Positive' if yeast buds and/or hyphae were observed
Was a sample collected for Syphilis testing?	Select 'Yes' or 'No'. If 'No', then the remaining items for Syphilis testing do not need to be completed. Proceed to 'Was a vaginal sample collected for Trichomonas testing via NAAT?'
Date of collection	Record the date that the first specimen(s) was collected, NOT the date the results were reported or recorded on the form for this visit. A complete date is required.

CONFIDENTIAL DOCUMENT

Field	Instructions
Syphilis screening test	If the result of the Syphilis screening test is 'Reactive,' complete the Syphilis confirmatory test results. Enter 'Not reported' in the event that a specimen was collected, but the result is not available due to specimen loss or damage.  If the result is "non-reactive" or "not reported", skip to 'Was a vaginal sample collected for Trichomonas testing via NAAT?'
Syphilis titer	Record the titer in the format 1: XXXX. When completing this form in Medidata Rave, please include the "1:" in the same field for the syphilis titer.
Syphilis confirmatory test	If the result of the Syphilis screening test is 'Reactive,' complete the Syphilis confirmatory test results (either 'Negative,' 'Positive,' or 'Indeterminate' or 'Not done').
Was a vaginal sample collected for Trichomonas testing via NAAT?	If Trichomonas testing via NAAT was not done or not collected, select the 'No' option for "Was a vaginal sample collected for Trichomonas testing via NAAT?" and do not complete the "Date of collection" or corresponding test result. Proceed to 'Was a sample collected for NAAT for GC/CT?'
Date of collection	Record the date that the first specimen(s) was collected, NOT the date the results were reported or recorded on the form for this visit. A complete date is required.
Trichomonas test	If "Trichomonas" was not done, select the 'Not done' option. If the specimen was collected, complete the test result (either 'Positive' or 'Negative').
Was a sample collected for NAAT for GC/GT?	If "NAAT for GC/GT" was not done or not collected, select the 'No' option for "Was a sample collected for NAAT for GC/CT?" and do not complete the "Date of collection" or corresponding test results. Proceed to ' Was a swab collected for genital lesion HSV testing?'
Date of collection	Record the date that the first specimen(s) was collected, NOT the date the results were reported or recorded on the form for this visit. A complete date is required.
N. gonorrhoeae	If "N. gonorrhoeae" was not done or not collected, select the 'Not done' option. If the specimen was collected, complete the test result (either 'Positive' or 'Negative').
C. trachomatis	If "C. trachomatis" was not done or not collected, select the 'Not done' option. If the specimen was collected, complete the test result (either 'Positive' or 'Negative').
Was a swab collected for genital lesion HSV testing?	If "genital lesion HSV testing" was not done or not collected, select the 'No' option for "Was a swab collected for genital lesion HSV testing?" and do not complete the "Date of collection" or corresponding test result.
Date of collection	Record the date that the first specimen(s) was collected, NOT the date the results were reported or recorded on the form for this visit. A complete date is required.

### ***Local Laboratory Results***

#### **Purpose:**

This form is used to provide data on the participant's baseline and follow-up laboratory test results.

#### **General Instructions:**

**CONFIDENTIAL DOCUMENT**

Use this form to report the serum chemistries from specimens collected at Visit 1.0 - Screening, Visit 2.0 - Enrollment, Visit 5.0 – Day 28, Visit 11.0 - Day 90, and as indicated during the study. Record results on this form as they become available.

If any or all of the lab tests listed on this form are repeated (re-drawn) between the Screening and Enrollment Visit, document the repeated results on the same Local Laboratory Results form. If the participant enrolls, the updated results should be submitted into the study database.

At Screening, record any applicable diagnoses within the Baseline Medical History Log form, when applicable.

During follow-up, if a test result(s) recorded on this form indicates that the participant has a new (or increased severity) laboratory-confirmed infection or diagnosis, this infection/diagnosis must be recorded as an adverse event on an Adverse Event (AE) Log form.

*Entering Laboratory Results*

- The lab that collected the specimens used for these tests should be selected from the Lab dropdown list at the top of the form. The units and lab ranges for each result will be populated at the bottom of the form after selecting the appropriate lab.
 

**Note.** The Demographics eCRF needs to be entered prior to entering data on the Local Laboratory Results eCRF because the derived age from the Date of Birth on the Demographics eCRF is used to populate the reference ranges.
- For each lab test (e.g., Serum Chemistries), enter the specimen collection date at the top of the form for that specific test each time this form is completed unless it was not collected.
- For each individual lab result (e.g. AST, ALT, Creatinine, Albumin), record the numeric results in the appropriate field at the bottom of the form.

Subject: 990248595  
 Page: Local Laboratory Results - V1.0 - Screening

Lab **Test** View Ranges

Was a sample collected for blood chemistries? Yes

Collection date 1 MAY 2018

AST (SGOT) severity grade not gradable

AST (SGOT) adverse event

ALT (SGPT) severity grade not gradable

ALT (SGPT) Adverse event

Creatinine severity grade not gradable

Creatinine Adverse event

Albumin severity grade not gradable

Albumin adverse event

Source document

	Data	Range Status	Unit	Range
AST (SGOT)	16		U/L	5 - 40
ALT (SGPT)	25		U/L	5 - 40
Creatinine	1.0		mg/dL	0.6 - 1.1
Albumin	40		g/dL	35 - 50

Printable Version View PDF Icon Key  
 CRF Version 888 - Page Generated: 21 May 2018 10:33:22 Pacific Daylight Time

Save Cancel

- Enter the severity grade at the top of the form for that specific result. The following results require entry of the severity grade (if applicable):

- **SERUM CHEMISTRIES:** AST (SGOT), ALT (SGPT), Creatinine, Albumin

See the *Severity Grade* section for further instructions on completing the severity grade.

#### *Lab Result Units and Rounding*

- Results should be documented on the form using the units used in the current version of the DAIDS AE Grading Table. If the units present on your source results report do not match the units on the form and in the DAIDS Toxicity Table, results must be converted before entry into the eCRF. An optional lab units conversion tool is available on Atlas:

<https://atlas.scharp.org/cpas/project/Collaborators/Lab%20Unit%20Conversion%20Tool/begin.vi>  
[ew](#)

- Note that the following units are equivalent:

IU/L = U/L

I/l x 100 = %

$10^9/L = 10^3/mm^3 = 10^3/\mu L$

The following analytes should be recorded in the following format:

- **AST/SGOT** (U/L for all sites): Up to a two digit integer is allowable for the AST/SGOT analyte.
- **ALT/SGPT** (U/L for all sites): Up to a two digit integer is allowable for the AST/SGOT analyte.
- **Creatinine** (mg/dL for all sites): It may be necessary to round the result reported by the lab up or down to the tenth place. For example, a lab-reported Creatinine value of 0.54 mg/dL would be recorded as 0.5 mg/dL.
- **Albumin** (g/dL for all sites): should be recorded using the same level of precision according to the source laboratory results document.

#### *Reporting Severity Grade*

- Record the severity grade at the top of the form by selecting from the drop-down menu for each corresponding lab analyte when applicable. If the analyte does not meet criteria for severity grade 1 or greater per the current version of the DAIDS Toxicity table, select the 'Not gradable' option.
- The severity grade options are as follows:
  - Grade 1 – Mild
  - Grade 2 – Moderate
  - Grade 3 – Severe
  - Grade 4 – Potentially life-threatening
  - Not gradable
- If any values meet the criteria for severity grade 1 or greater, according to the appropriate *DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events*, record the grade. If the value is below Grade 1, select the option 'not gradable'.
- Always compare the severity grade range to the value that was recorded on the form (not the lab-reported value).

**CONFIDENTIAL DOCUMENT**

- When working with calculated severity grade ranges (e.g., 1.1–1.5 times the site lab upper limit of normal), the calculated range may have more significant digits than the lab result.
  - Treat all missing digits in the lab value as zeros.
  - If the lab value falls between two calculated severity grade ranges, assign it the higher grade.
- Record any Grade 1 or higher lab values on the “Baseline Medical History” log or “Adverse Event” log as applicable.
- If an abnormal lab finding meets AE reporting criteria, select the corresponding AE within the drop-down menu. Please note that the AE must be entered within the Ongoing Logs folder prior to completing this form in order to link the associated AE.

## *Hematology*

### **Purpose:**

This form is used to provide data on the participant’s laboratory test results.

### **General Information/Instructions:**

Use this form to report the hematology and differential test results obtained from specimens collected at Visit 1.0 - Screening, Visit 2.0 - Enrollment, Visit 5.0 – Day 28, Visit 11.0 - Day 90, and as indicated during the study. If the Hematology form is needed at Enrollment, use the “Add Event” drop down menu on the participant’s home page.

If any or all of the lab tests listed on this form are repeated (re-drawn) between the Screening and Enrollment Visit, document the repeated results on the same Local Laboratory Results form. If the participant enrolls, the updated results should be submitted into the study database.

At Screening, record any applicable diagnoses within the Baseline Medical History Log eCRF, when applicable.

During follow-up, if a test result(s) recorded on this form indicates that the participant has a new (or increased severity) laboratory-confirmed infection or diagnosis, this infection/diagnosis must be recorded as an adverse event on an Adverse Event (AE) Log form.

### *Entering Laboratory Results*

- The lab that collected the specimens used for these tests should be selected from the Lab dropdown list at the top of the form. The units and lab ranges for each result will be populated at the bottom of the form after selecting the appropriate lab.  
**Note:** The Demographics eCRF needs to be entered prior to entering data on the Hematology eCRF because the derived age from the Date of Birth on the Demographics eCRF is used to populate the reference ranges.
- For each lab test (Hematology and Differential), enter the specimen collection date at the top of the form for that specific test each time this form is completed unless it was not collected.

**CONFIDENTIAL DOCUMENT**

- For each individual lab result (Hemoglobin, Hematocrit, MCV, Platelets, WBC, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils), record the numeric results in the appropriate field at the bottom of the form.

Subject: 999586294  
Page: Hematology - V1.0 - Screening

Lab TEST View Ranges

Was a hematology sample collected?	Yes	✓	⚙	🗑
Hematology Collection Date	1 MAR 2017	✓	⚙	🗑
Hemoglobin severity grade	not gradable	✓	⚙	🗑
Hemoglobin Adverse event		✓	⚙	🗑
Platelets severity grade	not gradable	✓	⚙	🗑
Platelets Adverse event		✓	⚙	🗑
WBC severity grade	not gradable	✓	⚙	🗑
WBC Adverse event		✓	⚙	🗑
<b>DIFFERENTIAL</b>				
Was a differential done?	Yes	✓	⚙	🗑
Differential Collection Date	1 MAR 2017	✓	⚙	🗑
Neutrophils severity grade	not gradable	✓	⚙	🗑
Neutrophils Adverse event		✓	⚙	🗑
Lymphocytes severity grade	not gradable	✓	⚙	🗑
Lymphocytes Severity Grade - Calculated	not gradable	✓	⚙	🗑
Lymphocytes Adverse event		✓	⚙	🗑
	Data	Range Status	Unit	Range
Hemoglobin	11.8		g/dL	11.6 - 14.6
Hematocrit	34.5		%	34.1 - 43.3
MCV	82.6		fL	82.6 - 97.4
Platelets	169		10 <sup>3</sup> /μL	156 - 369
WBC	3.9		10 <sup>3</sup> /μL	3.8 - 10.6
Neutrophils	2.56		10 <sup>3</sup> /μL	2.24 - 7.68

- Enter the severity grade at the top of the form for that specific result. The following results require entry of the severity grade (if applicable):
  - HEMATOLOGY:** Hemoglobin, Platelets, WBC
  - DIFFERENTIAL:** Neutrophils, Lymphocytes

See the *Severity Grade* section for further instructions on completing the severity grade.

*Lab Result Units and Rounding*

- Results should be documented on the form using the units used in the current version of the DAIDS AE Grading Table. If the units present on your source results report do not match the units on the form and in the DAIDS Toxicity Table, results must be converted before entry into the eCRF. An optional lab units conversion tool is available on Atlas: <https://atlas.scharp.org/cpas/project/Collaborators/Lab%20Unit%20Conversion%20Tool/begin.vi>

- Note that the following units are equivalent:

$$IU/L = U/L \qquad I/l \times 100 = \% \qquad 10^9/L = 10^3/mm^3 = 10^3/\mu L$$

The following analytes should be recorded in the following format:

- **Hemoglobin** (g/dL for all sites): Round Hemoglobin values up or down to the nearest tenth place. For example, a lab-reported Hemoglobin value of 11.06 g/dL would be recorded as 11.1 g/dL.
- **MCV** (fl for all sites) – Enter value up to 1 decimal for MCV analyte.
- **Platelets** ( $10^3/\mu\text{L}$  for all sites): Up to a three-digit whole integer is allowable for Platelets.
- **WBC** ( $10^3/\mu\text{L}$ ), **Neutrophils** (cells/ $\text{mm}^3$ ), **Lymphocytes** (cells/ $\text{mm}^3$ ), **Monocytes** (cells/ $\text{mm}^3$ ), **Eosinophils** (cells/ $\text{mm}^3$ ), **Basophils** (cells/ $\text{mm}^3$ ): Enter value using the same level of precision according to source laboratory results document.

#### *Reporting Severity Grade*

- Record the severity grade at the top of the form by selecting from the drop-down menu for each corresponding lab analyte when applicable. If the analyte does not meet criteria for severity grade 1 or greater per the DAIDS Toxicity table (Version 2.1), select the 'Not gradable' option.
- The severity grade options are as follows:
  - Grade 1 – Mild
  - Grade 2 – Moderate
  - Grade 3 – Severe
  - Grade 4 – Potentially life-threatening
  - Not gradable
- If any values meet the criteria for severity grade 1 or greater, according to the appropriate *DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events*, record the grade. If the value is below Grade 1, select the option 'not gradable'.
- Always compare the severity grade range to the value that was recorded on the form (not the lab-reported value).
- When working with calculated severity grade ranges (e.g., 1.1–1.5 times the site lab upper limit of normal), the calculated range may have more significant digits than the lab result.
  - Treat all missing digits in the lab value as zeros.
  - If the lab value falls between two calculated severity grade ranges, assign it the higher grade.
- Record any Grade 1 or higher lab values on the "Baseline Medical History Log" or "Adverse Event Log" eCRF(s) as applicable.
- If an abnormal lab finding meets AE reporting criteria, select the corresponding AE within the drop-down menu. Please note that the AE must be entered within the Ongoing Logs folder prior to completing this form in order to link the associated AE.

## *Hormone Tests*

### **Purpose:**

This form is used to document the participant's hormone test results.

### **General Instructions:**

Record specimen test results on this form as they become available from the local lab. This form is required at V2.0 – Enrollment and all follow-up visits through V11.0 – Day 90.

- Record if a specific test was done by entering 'Yes' or 'No' for item "Was a [hormone] sample collected?". If 'No' is selected, leave the applicable sub-items blank.

### **Item-specific Instructions:**

Field	Instructions
Date of Collection	Record the date that the hormone test was collected and NOT the date the results were reported or recorded within the form for this visit. A complete date is required.
Test Result	Record the result of the applicable test as recorded on the lab results form. Note that SHBG is only required at V2.0 – Enrollment and V11.0 – Day 90.
Progesterone	Select "<" or "=" as reported by the lab results form. For example, if a participant's progesterone value is reported as < 0.25, then select the "<" symbol. If there is no lower limit of detection (i.e. absence of the "<" symbol, then select the "=" symbol.
Estradiol	Select "<" or "=" as reported by the lab results form. For example, if a participant's estradiol value is reported as < 15 pg/mL, then select the "<" symbol. If there is no lower limit of detection (i.e. absence of the "<" symbol, then select the "=" symbol.

## *Pregnancy Test Results*

### **Purpose:**

This form is used to document the pregnancy test result as the result becomes available from the local lab.

### **General Instructions:**

This form is required at Visit 1.0 – Screening, Visit 2.0 – Enrollment, V4.0 – Day 14, V6.0 – Day 30, V9.0 – Day 60, V11.0 – Day 90, and at other visits if indicated. Note that this form is not used to document the results of the at-home pregnancy tests performed for the Phone Follow-up visits.

### **Item-specific Instructions:**

Field	Instructions
Was a pregnancy test done?	Record if a pregnancy test was done by entering 'Yes' or 'No'. If 'No' is selected, then end of form and leave remaining items blank. <ul style="list-style-type: none"> <li>If a pregnancy test was not done, please do NOT complete the "Date of Pregnancy Test", "time" or "Test result".</li> <li>If the sample was collected, then complete "Date of Pregnancy Test", "Time" and "Test result".</li> </ul>
Collection date	Record the date that the pregnancy test was collected and NOT the date the results were reported or recorded within the form for this visit. A complete date is required.
Collection time	Record the time that of sample collection using the 24-hour clock format.
Pregnancy test Result	Record the result of the pregnancy test - positive (pregnant) or negative (NOT pregnant) by selecting the appropriate radio button. If the result is <b>"Positive"</b> at a follow-up visit, then complete a Product Discontinuation eCRF, Study Discontinuation eCRF, and Pregnancy Report eCRF. If the result is <b>"Positive"</b> at the Screening or Enrollment visit, then the participant is not eligible and should not be enrolled into MTN-044.

### *Specimen Storage*

#### **Purpose:**

This form is used to document collection and storage of CVL, CVF, swab, gram stain, used vaginal ring, and plasma specimens by the local site laboratory during follow-up.

#### **General Instructions:**

Complete this form at V2.0 – Enrollment and follow-up visits Visit 3.0 – Day 2 through V14.0 – Day 93/94.

#### **Item-specific Instructions:**

Field	Instructions
Specimen Type	This field will be autopopulated to display specimens.
Was sample collected?	Select 'Yes' or 'No'. If 'No', then do not complete the date and time of collection and storage items.
Specimen Collection Date	Record the date that the first specimen(s) was collected. A complete date is required.
Specimen Collection Time	Record the time of sample collection in the 24-hour clock.
Was sample stored	Enter 'Stored' for specimens that are collected and sent to the lab for processing. If a specimen is not stored, select 'Not stored' and record the reason in the corresponding "If not stored, specify reason" text field provided.

## **BEHAVIORAL FORMS**

### ***Baseline Behavioral Questionnaire***

#### **Purpose:**

This form is used to document participant information on pregnancy prevention, vaginal practices, sexual behavior, ring acceptability and concerns, and any additional comments.

#### **General Instructions:**

This is an interviewer-administered form. Read each item aloud and record the participant's response. Complete this form at the V2.0 – Enrollment visit.

#### **Item-specific Instructions:**

<b>Field</b>	<b>Instructions</b>
Date of Assessment	A complete date is required.
<b>Pregnancy Prevention</b>	
Section A1: In your lifetime, have you ever used any of the following contraceptive methods?	<p>Read items a – q aloud. Select 'Yes' or 'No' for each contraceptive method.</p> <p>If 'Yes' for "Contraceptive/hormonal vaginal ring", please record which vaginal ring the participant used in the "If yes, specify" text field provided</p> <p>If 'Yes' for "Other", please record the participant's response in the "If other, please specify" text field provided.</p> <p>If all responses for items a – p are 'No', then item q "None – I have never used any contraception (birth control)" should be selected 'Yes'. If <i>any</i> response is 'Yes' for items a – p, then item q "None – I have never used any contraception (birth control)" should be selected 'No'.</p>
Section A2: In the past 30 days, have you used any of the following contraceptive methods?	<p>Read applicable items a – p aloud based on the 'Yes' responses in section A1 above and check all that apply. If any items in section A1 a – p are selected as 'No', then skip the corresponding items in Section A2 and leave these items blank. For example, if a participant has not used oral contraception in her lifetime (Item A1c is 'No'), then do not ask about oral contraception in Section A2.</p> <p>If 'Other' is checked, then specify the participant's response in the "If other, please specify" text field provided.</p>

CONFIDENTIAL DOCUMENT

<b>Vaginal Practices</b>	
Section B1: Have you ever in your life used/inserted any of the following?	<p>Read items a – l aloud and select ‘Yes’ or ‘No’ for each item.</p> <p>If ‘Yes’ for “Non-contraceptive vaginal ring”, please record which vaginal ring the participant used in the “If yes, specify” text field provided</p> <p>If “Douche or other personal hygiene product that is inserted inside the vagina” is ‘No’, then Item B2 “How many times did you douche vaginally in the past 3 months?” should have a response of ‘0’.</p> <p>If ‘Yes’ for “Other”, please record the participant’s response in the “If other, please specify” text field provided.</p>
<b>Sexual Behavior</b>	
Section C1: In your lifetime, what type(s) of sexual activity have you had?	<p>Read items a – b aloud and select ‘Yes’ or ‘No’ for each item.</p> <p>If item a “Vaginal sex” is ‘No’, then the response to item C2 “During the last act of vaginal sex that you had, was a condom used?” should be selected ‘Not applicable’ from the drop-down menu.</p>
Section C2: During the last act of vaginal sex that you had, was a condom used?	Read response categories aloud and select one response option based on the participant’s response.
Sections C3 and C4: How many sex partners...	<p>Record the number of sex partners based on the participant’s response. Note that item C4 should not be greater than item C3.</p> <p>If C3 is ‘0’, then enter ‘0’ for C4.</p>
<b>Ring acceptability and Concerns</b>	
Section D1: How worried are you about using one vaginal ring for 3 months?	Read response categories aloud and select the participant’s response from the drop-down list.
Section D2: Overall, how much do you like the ring?	Read response categories aloud and select the participant’s response from the drop-down list.
<b>Additional Comments</b>	
We are close to the end of the interview. Is there anything that we haven’t asked that you think we should have?	Record any additional comments reported by the participant in the text field provided. Up to 400 characters are allowed. If the participant does not have any additional comments to share, then note that in the text field provided.

### ***PUEV Behavioral Questionnaire***

#### **Purpose:**

This form is used to document participant information on ring acceptability, product preference, and any additional comments.

#### **General Instructions:**

**CONFIDENTIAL DOCUMENT**

This is an interviewer-administered form. Read each item aloud and record the participant's response. Complete this form at the V11.0 – Day 90 visit.

**Item-specific Instructions:**

Field	Instructions
Date of Assessment	A complete date is required.
<b>Ring Acceptability</b>	
Questions about her experiences with the vaginal ring.	<p>Read all items and response categories aloud. Based on the participant's response, select the applicable response from the drop-down menu.</p> <p>If item "Have you checked to see if the ring was still inside you?" is 'No', then leave 'How often did you check to see if it was still inside you?' and 'How did you typically check to see if the ring was still inside you?' blank.</p> <p>If 'How did you typically check to see if the ring was still inside you?' is 'Other', then specify the participant's response in the "If Other, specify" text field provided.</p> <p>If 'No' for "Overall, did you notice that your vagina was wetter?", leave "How much has your vagina being wetter bothered you?" blank.</p> <p>If 'No' for "Overall, did you notice that your vagina was drier?", leave "How much has your vagina being drier bothered you?" blank.</p> <p>If 'No' for "Overall have you experienced any other changes in your vagina while wearing the ring?", leave "How much as this change bothered you?" blank. If 'Yes' for this question, please record the participant's response in the "If yes, specify" text field provided.</p>
<b>Product Preference</b>	
Questions about the participant's experience with both the male condom and the vaginal ring.	Read all questions and response categories aloud. Based on the participant's response, select the applicable response from the drop-down menu.
<b>Additional Comments</b>	
Is there anything that we haven't asked that you think we should have?	Record any additional comments reported by the participant in the text field provided. If the participant does not have any additional comments to share, then note that in the text field provided. Up to 400 characters are allowed.
Is there anything else you would like to tell us about your experience with the ring?	Record any additional comments reported by the participant in the text field provided. If the participant does not have any additional comments to share, then note that in the text field provided. Up to 400 characters are allowed.

***Ring Outage SMS***

**Purpose:**

CONFIDENTIAL DOCUMENT

This form is used to document the participant's ring outage SMS data and ring outages reported at a visit.

**General Instructions:**

Complete this form at V6.0 - Day 30, V9.0 – Day 60, and V11.0 - Day 90 visits. Completion of this form is required at these visits, regardless of whether or not the participant submitted any SMS data on ring outages. Please reference the SMS Technical Manual and Section 05 of the SSP for further details on completing this form.

**Item-specific Instructions:**

Field	Instructions
Date of assessment	A complete date is required.
<i>Enter the first 3 fields after completing the log lines have been filled in. Update if the participant reports any additional outages during the visit.</i>	
Did the participant report any partial or full ring outages via SMS?	Review the "q1" and "q2" responses for each row from the SMS data output ("1" = yes, "2" = no). If all are no, then enter 'No' for this item. If at least one yes response is present, select 'Yes'.  At the V6.0 – Day 30 visit, include all SMS messages sent since the Enrollment visit. At the V9.0 – Day 60 visit, include all SMS messages sent since the V6.0 – Day 30 visit, or since the Enrollment visit, if the Day 30 visit was missed. At the V11.0 – Day 90 visit, include all SMS messages sent since the V9.0 – Day 60 visit or since the Day 30 visit, if the Day 60 visit was missed.
Did the participant report any partial or full ring outages at this visit (that were not reported by SMS)?	If the participant reports any outages that were not reported by SMS, select 'Yes'.
How many times did the participant report a full ring outage?	Review all SMS messages within the given study period, and enter the total number of full ring outages the participant experienced.  Specifically, add the values in the "q3" and "q4" columns from the SMS data output. If additional outages are reported at the visit, add the number of outages reported at the visit to the sum of "q3" and "q4".
<i>Complete one log line/row for each ring outage SMS received. Click "Add a new Log line" to add an additional entry. At the participant's visit, complete an additional entry for the period since the last SMS.</i>	
Date ring outage reported by participant	When reported by SMS, enter the date from the "Time Created" column from the SMS output. A complete date is required.  When reported at a clinic visit for the period of time since the last SMS, enter the date of the clinic visit. If reported at a clinic visit for a week for which SMS data was missing, enter the date the missing SMS was expected.

CONFIDENTIAL DOCUMENT

Was the ring outage reported by SMS or at the clinic visit?	When entering data from SMS, select 'SMS'.  When entering data reported by the participant at a clinic visit, select 'Participant report at visit'. If correcting data that was reported by SMS, correct applicable data and change to 'Participant report at visit'.
Did the ring ever partially fall out?	Enter the response based on the "q1" response from the SMS data output. Enter 'Yes' if q1 = 1, enter 'No' if q1 = 2..
Did the ring ever fully fall out?	Enter the response based on the "q3" response from the SMS data output. Enter 'Yes' if q3 > 0. Enter 'No' if q3 = 0.  If "no", skip to "Did the participant ever remove the ring?"
Number of times ring fell out fully	Enter the response based on the actual value entered in "q3".
Did the participant ever remove the ring?	Enter the response based on the "q4" response from the SMS data output. Enter 'Yes' if q4 > 0. Enter 'No' if q4 = 0.  If "Did the ring ever fully fall out?" and "Did the participant ever remove the ring?" both equal "no", end of log line.
Number of times ring was removed	Enter the response based on the actual value entered in "q4".
Was the ring out for more than 24 hours?	Enter the response based on the "q5" response from the SMS data output. Enter 'Yes' if q5 = 1, enter 'No' if q5 = 2.  If "yes", skip to "Ring was out of place/moved".
Was the ring out for more than 3 hours?	Enter the response based on the "q6" response from the SMS data output. Enter 'Yes' if q6 = 1, enter 'No' if q6 = 2.
Ring was out of place/moved	Enter the response based on the "q7" response from the SMS data output. Enter 'Yes' if q7 = 1, enter 'No' if q7 = 2.
Physical discomfort with the ring	Enter the response based on the "q8" response from the SMS data output. Enter 'Yes' if q8 = 1, enter 'No' if q8 = 2.
During menses	Enter the response based on the "q9" response from the SMS data output. Enter 'Yes' if q9 = 1, enter 'No' if q9 = 2.
Before, during or after sex	Enter the response based on the "q10" response from the SMS data output. Enter 'Yes' if q10 = 1, enter 'No' if q10 = 2.
Bathroom event /toilet (bowel movement or urination)	Enter the response based on the "q11" response from the SMS data output. Enter 'Yes' if q11 = 1, enter 'No' if q11 = 2.
Exercise or other activities	Enter the response based on the "q12" response from the SMS data output. Enter 'Yes' if q12 = 1, enter 'No' if q12 = 2.
Other	Enter the response based on the "q13" response from the SMS data output. Enter 'Yes' if q13 = 1, enter 'No' if q13 = 2.
Was the ring re-inserted?	Enter the response based on the "q14" response from the SMS data output. Enter 'Never' if q14 = 1, enter 'Sometimes' if q14 = 2, enter 'Often' if q14 = 3, enter 'Always' if q14 = 4.  If "never", end of form.

CONFIDENTIAL DOCUMENT

If yes, was the ring rinsed before it was re-inserted?	Enter the response based on the “q15” response from the SMS data output. Enter ‘Never’ if q15 = 1, enter ‘Sometimes’ if q15 = 2, enter ‘Often’ if q15 = 3, enter ‘Always’ if q15 = 4.
--	---

### ***Bleeding SMS***

#### **Purpose:**

This form is used to document the participant’s data on vaginal bleeding/spotting.

#### **General Instructions:**

Complete this form at follow-up Visit 3.0 through Visit 14.0. Completion of this form is required at these visits, regardless of whether or not the participant submitted any SMS data regarding vaginal bleeding/spotting. Please reference the SMS Technical Manual and Section 05 of the SSP for further details on completing this form.

#### **Item-specific Instructions:**

<b>Field</b>	<b>Instructions</b>
Date of assessment	A complete date is required.
<i>Enter the first 3 fields after completing the log lines have been filled in. Update if the participant reports any additional bleeding during the visit.</i>	
Did the participant report any vaginal spotting or bleeding via SMS?	If any responses in the “q1” column from the SMS data output are >1, then answer ‘Yes’ to “Did the participant report any vaginal spotting or bleeding via SMS?” If all responses in the “q1” column = 1, then enter ‘No’ for this item.
Did the participant report any vaginal spotting or bleeding at this visit (that was not reported by SMS)?	If the participant reports any spotting/bleeding that was not reported by SMS, select ‘Yes’.
On how many days did the participant experience vaginal spotting or bleeding?	Review all SMS messages since the previous visit, and enter the total number of spotting and/or bleeding days the participant experienced.  Specifically, count the number of rows from the “q1” column from the SMS data output that has a response >1 (2 = light bleeding, 3 = moderate bleeding, 4 = heavy bleeding) and enter this number as the number of spotting or bleeding days. If additional bleeding is reported at the visit, add the number of bleeding days reported at the visit to the sum of “q1” columns with a response > 1.
<i>Complete one log line/row for each bleeding SMS received. Click “Add a new Log line” to add an additional entry. At the participant’s visit, complete an additional entry for the period since the last SMS.</i>	

<p>Date of spotting/bleeding?</p>	<p>Enter the date from the “Time Created” column from the SMS output. A complete date is required.</p> <p>When reported at a clinic visit for the period of time since the last SMS, enter the date of the clinic visit. If reported at a clinic visit for a day for which SMS data was missing, enter the date the missing SMS was expected.</p>
<p>Was the report made by SMS or at the study visit?</p>	<p>When entering data from SMS, select ‘SMS’.</p> <p>When entering data reported by the participant at a clinic visit, select ‘visit’. If correcting data that was reported by SMS, correct applicable data and change to ‘visit’.</p>
<p>Description of spotting/bleeding</p>	<p>Enter one of the following responses as appropriate from the drop-down menu: “none”, “light bleeding/spotting”, “moderate bleeding”, “heavy bleeding” based on the code entered from the “q1” column (1 = none, 2 = light bleeding/spotting, 3 = moderate bleeding, 4 = heavy bleeding).</p> <p>If “none”, end of log line.</p>
<p>How bothersome was the spotting/bleeding?</p>	<p>Enter one of the following responses as appropriate from the drop-down menu: “Not at all”, “A little”, “Somewhat”, “Very much” based on the code entered from the “q2” column (1 = Not at all, 2 = A little, 3 = Somewhat, 4 = Very much)</p>